1393	Adeno	ad5	pol	M689V	nucleotide generic	4	4					4						Selective Modification of Adenovirus Replication Can Be Achieved through Rational Mutagenesis of the Adenovirus Type 5 DNA Polymerase	https://jvi.asm.org/content/jvi/86/19/10484.full.pdf	doi.org/10.1128/JVI.00739-12	Marker Transfer 	TK functional kinetic assay			04/02/2021	OJCharles	this is not resistance data		O
1394	Adeno	ad5	pol	C687S	nucleotide generic	4	4					4						Selective Modification of Adenovirus Replication Can Be Achieved through Rational Mutagenesis of the Adenovirus Type 5 DNA Polymerase	https://jvi.asm.org/content/jvi/86/19/10484.full.pdf	doi.org/10.1128/JVI.00739-12	Marker Transfer 	TK functional kinetic assay			04/02/2021	OJCharles	this is not resistance data		O
1395	Adeno	ad5	pol	R665K	nucleotide generic	4	4					4						Selective Modification of Adenovirus Replication Can Be Achieved through Rational Mutagenesis of the Adenovirus Type 5 DNA Polymerase	https://jvi.asm.org/content/jvi/86/19/10484.full.pdf	doi.org/10.1128/JVI.00739-12	Marker Transfer 	TK functional kinetic assay			04/02/2021	OJCharles	this is not resistance data		O
1396	Adeno	ad5	pol	I664V	nucleotide generic	2.5	2.5					2.5						Selective Modification of Adenovirus Replication Can Be Achieved through Rational Mutagenesis of the Adenovirus Type 5 DNA Polymerase	https://jvi.asm.org/content/jvi/86/19/10484.full.pdf	doi.org/10.1128/JVI.00739-12	Marker Transfer 	TK functional kinetic assay			04/02/2021	OJCharles	this is not resistance data - Donâ€™t trust this it was not repruceable between cell lines		O
1397	Adeno	ad5	pol	I664M	nucleotide generic	1.7	1.7					1.7						Selective Modification of Adenovirus Replication Can Be Achieved through Rational Mutagenesis of the Adenovirus Type 5 DNA Polymerase	https://jvi.asm.org/content/jvi/86/19/10484.full.pdf	doi.org/10.1128/JVI.00739-12	Marker Transfer 	TK functional kinetic assay			04/02/2021	OJCharles	this is not resistance data		O
1398	HSV1		UL23	E83K		37						71						Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1	https://www.sciencedirect.com/science/article/pii/S0166354206000313?via%3Dihub	doi.org/10.1016/j.antiviral.2006.01.010	Marker Transfer 	TK functional kinetic assay			29/01/2021	OJCharles			A
1399	HSV1		UL23	A189V		48						6.8						Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1	https://www.sciencedirect.com/science/article/pii/S0166354206000313?via%3Dihub	doi.org/10.1016/j.antiviral.2006.01.010	Marker Transfer 	TK functional kinetic assay			29/01/2021	OJCharles			A
1400	HSV1		UL23	R216C		37						21						Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1	https://www.sciencedirect.com/science/article/pii/S0166354206000313?via%3Dihub	doi.org/10.1016/j.antiviral.2006.01.010	Marker Transfer 	TK functional kinetic assay			29/01/2021	OJCharles			A
1401	HSV1		UL23	R163H		42						10						Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1	https://www.sciencedirect.com/science/article/pii/S0166354206000313?via%3Dihub	doi.org/10.1016/j.antiviral.2006.01.010	Marker Transfer 	TK functional kinetic assay			29/01/2021	OJCharles			A
1402	HSV1	Clinical isolate	UL23	P57H		42												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	dye uptake assay			04/02/2021	OJCharles		A2	A
1403	HSV1	Clinical isolate	UL23	K62N		12												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	PCR DNA hybridization assay			04/02/2021	OJCharles		A2	A
1404	HSV1	Clinical isolate	UL23	K62N		21												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	dye uptake assay			04/02/2021	OJCharles		A2	A
1405	HSV1	Clinical isolate	UL23	K62N		34												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	dye uptake assay			04/02/2021	OJCharles		A2	A
1406	HSV1	Clinical isolate	UL23	T63I		11												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	dye uptake assay			04/02/2021	OJCharles		A2	A
1407	HSV1	Clinical isolate	UL23	D228stop		36												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	dye uptake assay			04/02/2021	OJCharles		A2	A
1408	HSV1	Clinical isolate	UL23	D228stop		24												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	PCR DNA hybridization assay			04/02/2021	OJCharles		A2	A
1409	HSV2	Clinical isolate	UL23	T131P		25												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	dye uptake assay			04/02/2021	OJCharles		A2	A
1410	HSV1	Clinical isolate	UL23	T201P		22												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	dye uptake assay			04/02/2021	OJCharles		A2	A
1411	HSV1	Clinical isolate	UL23	R216C		16												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	PCR DNA hybridization assay			04/02/2021	OJCharles		A2	A
1412	HSV1	Clinical isolate	UL23	R216C		27												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	dye uptake assay			04/02/2021	OJCharles		A2	A
1413	HSV1	Clinical isolate	UL23	R222C		7.1												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	PCR DNA hybridization assay			04/02/2021	OJCharles		A2	A
1414	HSV1	Clinical isolate	UL23	R222C		9.8												Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients	https://academic.oup.com/jid/article/178/2/297/904713	doi.org/10.1086/515626	Isolated strain 	dye uptake assay			04/02/2021	OJCharles		A2	A
1415	HSV1	Clinical isolate	UL23	A156T		Polymorphism		Polymorphism										Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/	doi.org/10.1128/AAC.00977-15	Isolated strain 	PRA			07/01/2021	OJCharles	mutations not resolved by sequence	MacIntyre	A
1416	HSV1	Clinical isolate	UL23	C336Y		14												Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114104/	doi.org/10.1128/JVI.75.7.3105-3110.2001	Isolated strain 	PRA			04/02/2021	OJCharles			A
1417	HSV1	Clinical isolate	UL23	R222C		25												Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114104/	doi.org/10.1128/JVI.75.7.3105-3110.2001	Isolated strain 	PRA			04/02/2021	OJCharles			A
1418	HSV2	Clinical isolate	UL23	T131P		21												Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114104/	doi.org/10.1128/JVI.75.7.3105-3110.2001	Isolated strain 	PRA			04/02/2021	OJCharles			A
1419	HSV1	Clinical isolate	UL23	R176Q		8.9												Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114104/	doi.org/10.1128/JVI.75.7.3105-3110.2001	Isolated strain 	PRA			04/02/2021	OJCharles			A
1420	HSV1	Clinical isolate	UL23	Y172C		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles			A
1421	HSV1	Clinical isolate	UL23	L315S		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles			A
1422	HSV1	Clinical isolate	UL23	A174P		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles			A
1423	HSV1	Clinical isolate	UL23	Y53C		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles			A
1424	HSV1	Clinical isolate	UL23	E83N		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles	assumed typo in wt aa not position was Y83N		A
1425	HSV1	Clinical isolate	UL23	T245M		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles			A
1426	HSV1	Clinical isolate	UL23	L208H		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles			A
1427	HSV1	Clinical isolate	UL23	A156V		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles			A
1428	HSV1	Clinical isolate	UL23	V348I		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles			A
1429	HSV1	Clinical isolate	UL23	M121R		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles			A
1430	HSV1	Clinical isolate	UL23	G200C		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles			A
1431	HSV1	Clinical isolate	UL23	T103P		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles			A
1432	HSV1	Clinical isolate	UL23	T287M		Resistant												Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay	https://www.sciencedirect.com/science/article/pii/S0166093412004351?via%3Dihub	doi.org/10.1016/j.jviromet.2012.12.001	Isolated strain 	indirect ELISA			04/02/2021	OJCharles			A
1433	HSV1	AB047358	UL23	T65N		4.7												Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence	https://virologyj.biomedcentral.com/articles/10.1186/s12985-017-0728-2	doi.org/10.1186/s12985-017-0728-2	Marker Transfer 	PRA			04/02/2021	OJCharles			A
1434	HSV1	AB047358	UL23	P84S		10												Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence	https://virologyj.biomedcentral.com/articles/10.1186/s12985-017-0728-2	doi.org/10.1186/s12985-017-0728-2	Marker Transfer 	PRA			04/02/2021	OJCharles			A
1435	HSV1	AB047358	UL23	T245M		6.5												Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence	https://virologyj.biomedcentral.com/articles/10.1186/s12985-017-0728-2	doi.org/10.1186/s12985-017-0728-2	Marker Transfer 	PRA			04/02/2021	OJCharles			A
1436	HSV1	AB047358	UL23	C336Y		4.7												Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence	https://virologyj.biomedcentral.com/articles/10.1186/s12985-017-0728-2	doi.org/10.1186/s12985-017-0728-2	Marker Transfer 	PRA			04/02/2021	OJCharles			A
1437	HSV1	Clinical isolate	UL23	H105P		131		0.8										Rapid susceptibility testing for herpes simplex virus type 1 using real-time PCR	https://www.sciencedirect.com/science/article/pii/S1386653212003502?via%3Dihub	doi.org/10.1016/j.jcv.2012.09.004	Isolated strain 	PRA			04/02/2021	OJCharles			A
1438	HSV1	Clinical isolate	UL30	S724N		72		4										Rapid susceptibility testing for herpes simplex virus type 1 using real-time PCR	https://www.sciencedirect.com/science/article/pii/S1386653212003502?via%3Dihub	doi.org/10.1016/j.jcv.2012.09.004	Isolated strain 	PRA			04/02/2021	OJCharles			A
1439	HSV1	Clinical isolate	UL23	N376H		Polymorphism												Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis	https://academic.oup.com/jid/article/200/9/1402/851413	doi.org/10.1086/606028	Isolated strain 	PCR DNA hybridization assay			04/02/2021	OJCharles	Only sequences TK, so any Pol mutations are unnacounted for	KOS	A
1440	HSV1	Clinical isolate	UL23	L170P		Resistant												Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes	https://www.sciencedirect.com/science/article/pii/S0166354214000898?via%3Dihub	doi.org/10.1016/j.antiviral.2014.03.015	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1441	HSV1	Clinical isolate	UL23	R89Q		Polymorphism												Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients	https://www.sciencedirect.com/science/article/pii/S1386653213001157?via%3Dihub	doi.org/10.1016/j.jcv.2013.03.014	Isolated strain 	TK functional kinetic assay			04/02/2021	OJCharles	co-ocurs with 138vi and 322ml which are polymorphisms	KOS	A
1442	HSV1	Clinical isolate	UL23	V138I		Polymorphism												Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients	https://www.sciencedirect.com/science/article/pii/S1386653213001157?via%3Dihub	doi.org/10.1016/j.jcv.2013.03.014	Isolated strain 	TK functional kinetic assay			04/02/2021	OJCharles		KOS	A
1443	HSV1	Clinical isolate	UL23	G240E		Polymorphism												Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients	https://www.sciencedirect.com/science/article/pii/S1386653213001157?via%3Dihub	doi.org/10.1016/j.jcv.2013.03.014	Isolated strain 	TK functional kinetic assay			04/02/2021	OJCharles		KOS	A
1444	HSV1	Clinical isolate	UL23	S345P		Polymorphism												Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients	https://www.sciencedirect.com/science/article/pii/S1386653213001157?via%3Dihub	doi.org/10.1016/j.jcv.2013.03.014	Isolated strain 	TK functional kinetic assay			04/02/2021	OJCharles		KOS	A
1445	HSV1	Clinical isolate	UL23	D162N		Resistant												Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients	https://www.sciencedirect.com/science/article/pii/S1386653213001157?via%3Dihub	doi.org/10.1016/j.jcv.2013.03.014	Isolated strain 	TK functional kinetic assay			04/02/2021	OJCharles		KOS	A
1446	HSV1	Clinical isolate	UL23	P173L		Resistant												Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients	https://www.sciencedirect.com/science/article/pii/S1386653213001157?via%3Dihub	doi.org/10.1016/j.jcv.2013.03.014	Isolated strain 	TK functional kinetic assay			04/02/2021	OJCharles	many co occuring mutations	KOS	O
1447	HSV1	Clinical isolate	UL23	M182stop		Resistant												Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients	https://www.sciencedirect.com/science/article/pii/S1386653213001157?via%3Dihub	doi.org/10.1016/j.jcv.2013.03.014	Isolated strain 	TK functional kinetic assay			04/02/2021	OJCharles		KOS	A
1448	HSV1	Clinical isolate	UL23	R216H		Resistant												Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients	https://www.sciencedirect.com/science/article/pii/S1386653213001157?via%3Dihub	doi.org/10.1016/j.jcv.2013.03.014	Isolated strain 	TK functional kinetic assay			04/02/2021	OJCharles		KOS	A
1449	HSV1	Clinical isolate	UL23	R220H		Resistant												Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients	https://www.sciencedirect.com/science/article/pii/S1386653213001157?via%3Dihub	doi.org/10.1016/j.jcv.2013.03.014	Isolated strain 	TK functional kinetic assay			04/02/2021	OJCharles		KOS	A
1450	HSV1		UL30	Y818C		50	2.3	2.3			0.8	2.9						Characterization of DNA Polymerase-Associated Acyclovir-Resistant Herpes Simplex Virus Type 1: Mutations, Sensitivity to Antiviral Compounds, Neurovirulence, and In-Vivo Sensitivity to Treatment	https://www.jstage.jst.go.jp/article/yoken/66/5/66_404/_pdf/-char/en	doi.org/10.7883/yoken.66.404	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1451	HSV1		UL30	N815S		600	0.5	2.3			2.5	2.9						Characterization of DNA Polymerase-Associated Acyclovir-Resistant Herpes Simplex Virus Type 1: Mutations, Sensitivity to Antiviral Compounds, Neurovirulence, and In-Vivo Sensitivity to Treatment	https://www.jstage.jst.go.jp/article/yoken/66/5/66_404/_pdf/-char/en	doi.org/10.7883/yoken.66.404	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1452	HSV1		UL30	V817M		36	0.8	2.3			0.8	1.5						Characterization of DNA Polymerase-Associated Acyclovir-Resistant Herpes Simplex Virus Type 1: Mutations, Sensitivity to Antiviral Compounds, Neurovirulence, and In-Vivo Sensitivity to Treatment	https://www.jstage.jst.go.jp/article/yoken/66/5/66_404/_pdf/-char/en	doi.org/10.7883/yoken.66.404	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1453	HSV1		UL30	G841C		24	1	2.3			0.3	1.4						Characterization of DNA Polymerase-Associated Acyclovir-Resistant Herpes Simplex Virus Type 1: Mutations, Sensitivity to Antiviral Compounds, Neurovirulence, and In-Vivo Sensitivity to Treatment	https://www.jstage.jst.go.jp/article/yoken/66/5/66_404/_pdf/-char/en	doi.org/10.7883/yoken.66.404	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1454	HSV1		UL30	L702H		56	0.5	2.3			0.5	1.2						Characterization of DNA Polymerase-Associated Acyclovir-Resistant Herpes Simplex Virus Type 1: Mutations, Sensitivity to Antiviral Compounds, Neurovirulence, and In-Vivo Sensitivity to Treatment	https://www.jstage.jst.go.jp/article/yoken/66/5/66_404/_pdf/-char/en	doi.org/10.7883/yoken.66.404	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1455	HSV1	Clinical isolate	UL23	P268T		Polymorphism												Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients	https://academic.oup.com/jid/article/182/1/290/883239	doi.org/10.1086/315696	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1456	HSV1	Clinical isolate	UL23	D286E		Polymorphism												Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients	https://academic.oup.com/jid/article/182/1/290/883239	doi.org/10.1086/315696	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1457	HSV1	Clinical isolate	UL23	N376H		Polymorphism												Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients	https://academic.oup.com/jid/article/182/1/290/883239	doi.org/10.1086/315696	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1458	HSV1	Clinical isolate	UL23	N376H		Polymorphism												Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients	https://academic.oup.com/jid/article/182/1/290/883239	doi.org/10.1086/315696	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1459	HSV1		UL30	R881G		1.3		1										Resistance to Antiviral Inhibitors Caused by the Mutation S889A in the Highly-Conserved 885-GDTDS Motif of the Herpes Simplex Virus Type 1 DNA Polymerase	https://www.sciencedirect.com/science/article/pii/S004268228371439X?via%3Dihub	doi.org/10.1006/viro.1993.1439	Marker transfer 	PCR DNA hybridization assay			04/02/2021	OJCharles			A
1460	HSV1	KOS	UL23	R51W		Resistant	Polymorphism	Polymorphism			 	Resistant						Characterization of Herpes Simplex Virus Type 1 Thymidine Kinase Mutants Selected under a Single Round of High-Dose Brivudin	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1082774/#r5	doi.org/10.1128/JVI.79.9.5863-5869.2005	Lab induced strain 	PRA			04/02/2021	OJCharles		KOS	A
1480	HSV1	Clinical isolate	UL23	M130I		5												Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1	https://www.sciencedirect.com/science/article/pii/S0166354213002544?via%3Dihub	doi.org/10.1016/j.antiviral.2013.09.008	Isolated strain 	PRA			04/02/2021	OJCharles			A
1481	HSV1	TAS	UL23	C336Y		120	0.2											Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain	https://www.sciencedirect.com/science/article/pii/S0166354202001316?via%3Dihub	doi.org/10.1016/S0166-3542(02)00131-6	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1482	HSV1		UL23	T287M		500	1	0.3			1670	300						Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/	doi.org/10.1128/JVI.75.4.1761-1769.2001	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1483	HSV1	SC16	UL30	A719V		19		10										Related functional domains in virus DNA polymerases	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC553373/pdf/emboj00241-0168.pdf		Lab induced strain 	PRA			04/02/2021	OJCharles			A
1484	HSV1	SC16	UL30	G355D		Polymorphism												Related functional domains in virus DNA polymerases	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC553373/pdf/emboj00241-0168.pdf		Lab induced strain 	PRA			04/02/2021	OJCharles	Occurs only along with a co-resistant mutation		O
1485	HSV1	Clinical isolate	UL23	D162H		Resistant												Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization	https://www.sciencedirect.com/science/article/pii/S1386653204001246?via%3Dihub	doi.org/10.1016/j.jcv.2004.04.002	Isolated strain 	yield reduction assay (ELVIRA)			04/02/2021	OJCharles			A
1486	HSV1		UL23	R176Q		4.1												Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization	https://www.sciencedirect.com/science/article/pii/S1386653204001246?via%3Dihub	doi.org/10.1016/j.jcv.2004.04.002	Isolated strain 	yield reduction assay (ELVIRA)			04/02/2021	OJCharles			A
1487	HSV2		UL23	D229H		181												Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization	https://www.sciencedirect.com/science/article/pii/S1386653204001246?via%3Dihub	doi.org/10.1016/j.jcv.2004.04.002	Isolated strain 	yield reduction assay (ELVIRA)			04/02/2021	OJCharles			A
1488	HSV2		UL23	T288M		30												Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization	https://www.sciencedirect.com/science/article/pii/S1386653204001246?via%3Dihub	doi.org/10.1016/j.jcv.2004.04.002	Isolated strain 	yield reduction assay (ELVIRA)			04/02/2021	OJCharles			A
1489	HSV2		UL23	G56E		Resistant												Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization	https://www.sciencedirect.com/science/article/pii/S1386653204001246?via%3Dihub	doi.org/10.1016/j.jcv.2004.04.002	Isolated strain 	yield reduction assay (ELVIRA)			04/02/2021	OJCharles			A
1490	HSV1		UL23	R222H		20												Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization	https://www.sciencedirect.com/science/article/pii/S1386653204001246?via%3Dihub	doi.org/10.1016/j.jcv.2004.04.002	Isolated strain 	yield reduction assay (ELVIRA)	UL23	R363C	04/02/2021	OJCharles	unknwon comut		O
1491	HSV2		UL23	T202A		70		0.3										Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization	https://www.sciencedirect.com/science/article/pii/S1386653204001246?via%3Dihub	doi.org/10.1016/j.jcv.2004.04.002	Isolated strain 	yield reduction assay (ELVIRA)			04/02/2021	OJCharles			A
1492	HSV1		UL30	S724N		11												Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene	https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-81-3-639#tab2	doi.org/10.1099/0022-1317-81-3-639	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1493	HSV1		UL30	A136T		Polymorphism		Polymorphism										Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene	https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-81-3-639#tab2	doi.org/10.1099/0022-1317-81-3-639	Lab induced strain 	PRA			04/02/2021	OJCharles	R700M is poly in followup papers		A
1494	HSV1		UL30	L1007M		3.2												Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene	https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-81-3-639#tab2	doi.org/10.1099/0022-1317-81-3-639	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1495	HSV1		UL30	I1028T		1.6		1.5										Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene	https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-81-3-639#tab2	doi.org/10.1099/0022-1317-81-3-639	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1496	HSV1	KOS	UL30	A719V		4.2		2.3										DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions	https://journals.sagepub.com/doi/abs/10.1177/135965350701200502	doi.org/10.1177/1359653507012005	Lab induced strain 	Cytopathic effect			04/02/2021	OJCharles		KOS	A
1497	HSV1	KOS	UL30	S724N		6		4.7										DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions	https://journals.sagepub.com/doi/abs/10.1177/135965350701200502	doi.org/10.1177/1359653507012005	Lab induced strain 	Cytopathic effect			04/02/2021	OJCharles		KOS	A
1498	HSV1	KOS	UL30	T821M		4.7		2.9										DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions	https://journals.sagepub.com/doi/abs/10.1177/135965350701200502	doi.org/10.1177/1359653507012005	Lab induced strain 	Cytopathic effect			04/02/2021	OJCharles		KOS	A
1499	HSV1	KOS	UL30	L1007M		2												DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions	https://journals.sagepub.com/doi/abs/10.1177/135965350701200502	doi.org/10.1177/1359653507012005	Lab induced strain 	Cytopathic effect			04/02/2021	OJCharles		KOS	A
1500	HSV1	KOS	UL30	I1028T		1.5												DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions	https://journals.sagepub.com/doi/abs/10.1177/135965350701200502	doi.org/10.1177/1359653507012005	Lab induced strain 	Cytopathic effect			04/02/2021	OJCharles		KOS	A
1501	HSV1	KOS	UL30	A605V		4		10										Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants	https://www.sciencedirect.com/science/article/pii/S0166354297000545?via%3Dihub	doi.org/10.1016/S0166-3542(97)00054-5	Lab induced strain 	PRA			04/02/2021	OJCharles		KOS	A
1502	HSV1	KOS	UL30	S724N		8		6										Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants	https://www.sciencedirect.com/science/article/pii/S0166354297000545?via%3Dihub	doi.org/10.1016/S0166-3542(97)00054-5	Lab induced strain 	PRA			04/02/2021	OJCharles		KOS	A
1503	HSV1	KOS	UL30	F891C		10		10										Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants	https://www.sciencedirect.com/science/article/pii/S0166354297000545?via%3Dihub	doi.org/10.1016/S0166-3542(97)00054-5	Lab induced strain 	PRA			04/02/2021	OJCharles		KOS	A
1504	HSV1	KOS	UL30	N961K		4												Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants	https://www.sciencedirect.com/science/article/pii/S0166354297000545?via%3Dihub	doi.org/10.1016/S0166-3542(97)00054-5	Lab induced strain 	PRA			04/02/2021	OJCharles		KOS	A
1505	HSV1	TAS	UL30	N494S		Polymorphism												Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/	doi.org/10.1128/AAC.49.2.606-611.2005	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1506	HSV1	TAS	UL30	L702I		1	0.1	3				1						Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/	doi.org/10.1128/AAC.49.2.606-611.2005	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1507	HSV1	TAS	UL30	F716L		6	0.1	10				2.2						Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/	doi.org/10.1128/AAC.49.2.606-611.2005	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1508	HSV1	TAS	UL30	A719V		5.5	0.3	8				2.5						Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/	doi.org/10.1128/AAC.49.2.606-611.2005	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1509	HSV1	TAS	UL30	S724N		3	1	10				4						Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/	doi.org/10.1128/AAC.49.2.606-611.2005	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1510	HSV1	TAS	UL30	L778M		2.6	1	5				2.5						Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/	doi.org/10.1128/AAC.49.2.606-611.2005	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1511	HSV1	TAS	UL30	E798K		3												Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/	doi.org/10.1128/AAC.49.2.606-611.2005	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1512	HSV1	TAS	UL30	A834S		2												Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/	doi.org/10.1128/AAC.49.2.606-611.2005	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1513	HSV1	TAS	UL30	T839I		2.3												Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/	doi.org/10.1128/AAC.49.2.606-611.2005	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1514	HSV1	TAS	UL30	A910V		4												Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/	doi.org/10.1128/AAC.49.2.606-611.2005	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1515	HSV1	TAS	UL30	V958L		12												Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/	doi.org/10.1128/AAC.49.2.606-611.2005	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1516	HSV1	TAS	UL30	R959H		4.6												Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/	doi.org/10.1128/AAC.49.2.606-611.2005	Lab induced strain 	PRA			04/02/2021	OJCharles			A
1517	HSV1		UL23	Y53D		Resistant												Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity	https://www.sciencedirect.com/science/article/pii/S0166354212002239?via%3Dihub#b0010	doi.org/10.1016/j.antiviral.2012.09.016	Marker Transfer 	TK functional kinetic assay			04/02/2021	OJCharles			A
1518	HSV1		UL23	L170P		Resistant												Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity	https://www.sciencedirect.com/science/article/pii/S0166354212002239?via%3Dihub#b0010	doi.org/10.1016/j.antiviral.2012.09.016	Marker Transfer 	TK functional kinetic assay			04/02/2021	OJCharles			A
1519	HSV1		UL23	A207P		Resistant												Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity	https://www.sciencedirect.com/science/article/pii/S0166354212002239?via%3Dihub#b0010	doi.org/10.1016/j.antiviral.2012.09.016	Marker Transfer 	TK functional kinetic assay			04/02/2021	OJCharles			A
1520	HSV1	Clinical isolate	UL23	Y172C		80												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1521	HSV1	Clinical isolate	UL30	S724N		5												Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/	doi.org/10.1128/AAC.00977-15	Isolated strain 	PRA			04/02/2021	OJCharles		MacIntyre	A
1522	HSV1	Clinical isolate	UL23	N23S		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1523	HSV1	Clinical isolate	UL23	K36E		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1524	HSV1	Clinical isolate	UL23	L42P		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1525	HSV1	Clinical isolate	UL23	G251C		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1526	HSV1	Clinical isolate	UL23	A265T		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1527	HSV1	Clinical isolate	UL23	V267L		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1528	HSV1	Clinical isolate	UL23	P268T		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1529	HSV1	Clinical isolate	UL23	D286E		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1530	HSV1	Clinical isolate	UL23	N376H		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1531	HSV1	Clinical isolate	UL23	V348I		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1532	HSV1	Clinical isolate	UL30	F248L		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1533	HSV1	Clinical isolate	UL30	A1203T		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1534	HSV1	Clinical isolate	UL30	R330A		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			14/04/2021	OJCharles		Mackityre	A
1535	HSV1	Clinical isolate	UL23	I143V		Resistant												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	only co-occurs with unknown R256W	Mackityre	O
1536	HSV1	Clinical isolate	UL23	R256W		Resistant												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	only co-occurs with unknown I143V	Mackityre	O
1537	HSV1	Clinical isolate	UL23	Y172C		Resistant	Polymorphism	Polymorphism			Resistant	Resistant						Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			04/05/2021	OJCharles			A
1538	HSV1	Clinical isolate	UL23	A174P		Resistant												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay	UL30	D1103H	04/02/2021	OJCharles	only co-occurs with unknown mutation		O
1539	HSV1	Clinical isolate	UL23	L315S		Resistant												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1540	HSV1	Clinical isolate	UL30	P1124H		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1541	HSV1	Clinical isolate	UL30	T1208A		Polymorphism												Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1542	HSV1	Clinical isolate	UL30	A566T		Polymorphism		Polymorphism										Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	Cannot be inferred		O
1543	HSV1	Clinical isolate	UL30	D1103H		Polymorphism	Polymorphism	Polymorphism			Polymorphism	Polymorphism						Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S0166354210003864?via%3Dihub	doi.org/10.1016/j.antiviral.2010.03.002	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	Cannot be inferred		O
1544	HSV1	Clinical isolate	UL23	R222C		Resistant												Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes	https://www.sciencedirect.com/science/article/pii/S0166354214000898?via%3Dihub	doi.org/10.1016/j.antiviral.2014.03.015	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1545	HSV1	Clinical isolate	UL23	G200D		25												Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes	https://www.sciencedirect.com/science/article/pii/S0166354214000898?via%3Dihub	doi.org/10.1016/j.antiviral.2014.03.015	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1546	HSV1		UL23	P131S		20												Thymidine Kinase Mutations Conferring Acyclovir Resistance in Herpes Simplex Type 1 Recombinant Viruses	https://aac.asm.org/content/aac/50/11/3889.full.pdf	 doi.org/10.1128/AAC.00889-06	Marker transfer 	PRA			04/02/2021	OJCharles			A
1547	HSV1		UL23	C336Y		30												Thymidine Kinase Mutations Conferring Acyclovir Resistance in Herpes Simplex Type 1 Recombinant Viruses	https://aac.asm.org/content/aac/50/11/3889.full.pdf	 doi.org/10.1128/AAC.00889-06	Marker transfer 	PRA			04/02/2021	OJCharles			A
1548	HSV1	F	UL23	Q125H		13.3						5.3						Acyclovir Sensitivity and Neurovirulence of Herpes Simplex Virus Type 1 with Amino Acid Substitutions in the Viral Thymidine Kinase Gene, Which Were Detected in the Patients with Intractable Herpes Simplex Encephalitis Previously Reported	https://www.jstage.jst.go.jp/article/yoken/71/5/71_JJID.2018.176/_pdf/-char/en		Recombinant BAC 	PRA			04/02/2021	OJCharles		F	A
1549	HSV1	F	UL23	R41H		0.8												Acyclovir Sensitivity and Neurovirulence of Herpes Simplex Virus Type 1 with Amino Acid Substitutions in the Viral Thymidine Kinase Gene, Which Were Detected in the Patients with Intractable Herpes Simplex Encephalitis Previously Reported	https://www.jstage.jst.go.jp/article/yoken/71/5/71_JJID.2018.176/_pdf/-char/en		Recombinant BAC 	PRA			04/02/2021	OJCharles		F	A
1550	HSV1	F	UL23	A156V		0.9												Acyclovir Sensitivity and Neurovirulence of Herpes Simplex Virus Type 1 with Amino Acid Substitutions in the Viral Thymidine Kinase Gene, Which Were Detected in the Patients with Intractable Herpes Simplex Encephalitis Previously Reported	https://www.jstage.jst.go.jp/article/yoken/71/5/71_JJID.2018.176/_pdf/-char/en		Recombinant BAC 	PRA			04/02/2021	OJCharles		F	A
1551	HSV1	Clinical isolate	UL23	A37V		Polymorphism												HSV susceptibility to acyclovir - genotypic and phenotypic characterization	https://journals.sagepub.com/doi/10.3851/IMP3279	doi.org/10.3851/IMP3279	Isolated strain 	PRA			04/02/2021	OJCharles			A
1552	HSV1	Clinical isolate	UL23	H283N		Polymorphism												HSV susceptibility to acyclovir - genotypic and phenotypic characterization	https://journals.sagepub.com/doi/10.3851/IMP3279	doi.org/10.3851/IMP3279	Isolated strain 	PRA			04/02/2021	OJCharles			A
1553	HSV1	Clinical isolate	UL30	G641R		1		Polymorphism										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1554	HSV1	Clinical isolate	UL30	G645D		1		Polymorphism										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1555	HSV1	Clinical isolate	UL30	E649G		1.3		Polymorphism										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1556	HSV1	Clinical isolate	UL30	G679D		1		Polymorphism										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1557	HSV1	Clinical isolate	UL30	R681L		1		Polymorphism										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1558	HSV1	Clinical isolate	UL30	I966M		2.5		Polymorphism										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1559	HSV1	Clinical isolate	UL23	E43A		1.3												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	methodology is not explicit, were these individually transferred, or simply the experimentalists feeling?		O
1560	HSV1	Clinical isolate	UL23	L50M		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	methodology is not explicit, were these individually transferred, or simply the experimentalists feeling?		O
1561	HSV1	Clinical isolate	UL23	L68R		1.2												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	methodology is not explicit, were these individually transferred, or simply the experimentalists feeling?		O
1562	HSV1	Clinical isolate	UL23	E43A		1.3												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1563	HSV1	Clinical isolate	UL23	L50M		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1564	HSV1	Clinical isolate	UL23	L68R		1.5												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1565	HSV1	Clinical isolate	UL23	S74L		39		1										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	co-occurs with known resmut or other unknown mutant		O
1566	HSV1	Clinical isolate	UL23	Q109K		1		1.6										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1567	HSV1	Clinical isolate	UL23	A133V		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1568	HSV1	Clinical isolate	UL23	A136N		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	A is not the tk wt AA have emailed author		O
1569	HSV1	Clinical isolate	UL23	S150L		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1570	HSV1	Clinical isolate	UL23	P154S		84		1.1										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	co-occurs with known resmut or other unknown mutant		O
1571	HSV1	Clinical isolate	UL23	L159R		56		1.4										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	co-occurs with known resmut or other unknown mutant		O
1572	HSV1	Clinical isolate	UL23	E225L		25		2.2										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	co-occurs with known resmut or other unknown mutant		O
1573	HSV1	Clinical isolate	UL23	L242P		18		1										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1574	HSV1	Clinical isolate	UL23	Y248H		53		0.85										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	co-occurs with known resmut or other unknown mutant		O
1575	HSV1	Clinical isolate	UL23	D258N		1.3												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1576	HSV1	Clinical isolate	UL23	S263L		1.6												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1577	HSV1	Clinical isolate	UL23	P280S		1.3												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1578	HSV1	Clinical isolate	UL23	N301S		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1579	HSV1	Clinical isolate	UL23	A316S		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1580	HSV1	Clinical isolate	UL23	M322L		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1581	HSV1	Clinical isolate	UL23	I326V		1.3												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1582	HSV1	Clinical isolate	UL23	D330A		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	methodology is not explicit, were these individually transferred, or simply the experimentalists feeling?		O
1583	HSV1	Clinical isolate	UL23	D338H		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1584	HSV1	Clinical isolate	UL23	Q342H		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1585	HSV1	Clinical isolate	UL23	T344I		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1586	HSV1	Clinical isolate	UL23	Q349R		1												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1587	HSV1	Clinical isolate	UL23	V352L		1.9												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1588	HSV1	Clinical isolate	UL23	R370W		1.9												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1589	HSV1	Clinical isolate	UL23	E371D		1.9												UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles			A
1590	HSV1	Clinical isolate	UL5	L49I		20		10										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	co-occurs with other unknown mutants		O
1591	HSV1	Clinical isolate	UL5	L138V		19		8.6										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	co-occurs with other unknown mutants		O
1592	HSV1	Clinical isolate	UL5	S173L		53		1.5										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	co-occurs with other unknown mutants		O
1593	HSV1	Clinical isolate	UL5	A280T		39		1										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	co-occurs with other unknown mutants		O
1594	HSV1	Clinical isolate	UL5	A575V		39		1										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	co-occurs with other unknown mutants		O
1595	HSV1	Clinical isolate	UL5	V600A		19		8.6										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	co-occurs with other unknown mutants		O
1596	HSV1	Clinical isolate	UL5	A602T		19		8.6										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	methodology is not explicit, were these individually transferred, or simply the experimentalists feeling?		O
1597	HSV1	Clinical isolate	UL5	D862N		20		10										UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients	https://www.sciencedirect.com/science/article/pii/S0166354219300452?via%3Dihub	doi.org/10.1016/j.antiviral.2019.05.012	Isolated strain 	dye uptake assay			04/02/2021	OJCharles	co-occurs with other unknown mutants		O
1598	HSV1	Clinical isolate	UL23	L340R		14												Input of recombinant phenotyping for the characterization of a novel acyclovir-resistance mutation identified in a patient with recurrent herpetic keratitis	https://www.sciencedirect.com/science/article/pii/S0166354219302700?via%3Dihub	doi.org/10.1016/j.antiviral.2019.06.007	Isolated strain 	PRA			04/02/2021	OJCharles		KOS	A
1599	HSV1		UL23	L340R		34												Input of recombinant phenotyping for the characterization of a novel acyclovir-resistance mutation identified in a patient with recurrent herpetic keratitis	https://www.sciencedirect.com/science/article/pii/S0166354219302700?via%3Dihub	doi.org/10.1016/j.antiviral.2019.06.007	Recombinant BAC 	PRA			04/02/2021	OJCharles		KOS	A
1600	HSV1		UL23	R216H		Resistant												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles			A
1601	HSV1		UL23	L170P		Resistant												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1602	HSV1		UL23	S181N		Resistant												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1603	HSV1		UL23	Q15K		Polymorphism												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1604	HSV1		UL23	R20C		Polymorphism												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1605	HSV1		UL23	R32H		Polymorphism												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1606	HSV1		UL23	E43A		Polymorphism												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1607	HSV1		UL23	E43D		Polymorphism												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1608	HSV1		UL23	G61E		Resistant												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1609	HSV1		UL23	R89H		Polymorphism												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1610	HSV1		UL23	A93V		Resistant												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1611	HSV1		UL23	M121K		Resistant												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1612	HSV1		UL23	A156V		Polymorphism												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1613	HSV1		UL23	R163G		Resistant												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1614	HSV1		UL23	del173		Resistant												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1615	HSV1		UL23	V238F		Resistant												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1616	HSV1		UL23	N244H		Polymorphism												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1617	HSV1		UL23	G264V		Resistant												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1618	HSV1		UL23	P269S		Polymorphism												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1619	HSV1		UL23	G271V		Polymorphism												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1620	HSV1		UL23	S276N		Polymorphism												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1621	HSV1		UL23	I326V		Polymorphism												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1622	HSV1		UL23	N376*		Resistant												Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays	https://www.sciencedirect.com/science/article/pii/S016609341730071X?via%3Dihub	doi.org/10.1016/j.jviromet.2017.05.013	Lab induced strain 	TK functional kinetic assay			04/02/2021	OJCharles		JQ352247.1	A
1623	HSV2		UL23	R220T		Polymorphism												Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey	https://www.sciencedirect.com/science/article/pii/S0166354213002581?via%3Dihub#tblfn8	doi.org/10.1016/j.antiviral.2013.09.012	Isolated strain 	PRA			04/02/2021	OJCharles			A
1624	HSV2		UL30	A1213T		Polymorphism												Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey	https://www.sciencedirect.com/science/article/pii/S0166354213002581?via%3Dihub#tblfn8	doi.org/10.1016/j.antiviral.2013.09.012	Isolated strain 	PRA			04/02/2021	OJCharles	M1213 original have inferred type		A
1625	HHV6b		U38	R798I	4.2		118	1.2										Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection	https://www.sciencedirect.com/science/article/pii/S0166354207005001?via%3Dihub	doi.org/10.1016/j.antiviral.2007.12.004	Lab induced strain 	qPCR			04/02/2021	OJCharles		http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=nucleotide&doptcmdl=genbank&term=AB021506	A
1626	HHV6b		U38	A961V	Resistant													Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo	https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-82-11-2767	doi.org/10.1099/0022-1317-82-11-2767	Lab induced strain 	ELISA			04/02/2021	OJCharles	cannot infer		O
1627	HHV6b		U69	M318V	Resistant													Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo	https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-82-11-2767	doi.org/10.1099/0022-1317-82-11-2767	Lab induced strain 				04/02/2021	OJCharles	cannot infer		O
1628	HHV6b	Z29	U69	M318V	Resistant													Mapping ganciclovir resistance in the human herpesvirus?6 U69 protein kinase	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.10510	doi.org/10.1002/jmv.10510	Marker transfer 	PRA			04/02/2021	OJCharles		Z29	A
1629	HHV6b	Z29	U69	L213I	Polymorphism													Mapping ganciclovir resistance in the human herpesvirus?6 U69 protein kinase	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.10510	doi.org/10.1002/jmv.10510	Marker transfer 	PRA			04/02/2021	OJCharles		Z29	A
1630	HHV6b	Z29	U69	C448G	Resistant													Mapping ganciclovir resistance in the human herpesvirus?6 U69 protein kinase	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.10510	doi.org/10.1002/jmv.10510	Marker transfer 	PRA			04/02/2021	OJCharles		Z29	A
1631	HHV6b	Z29	U69	C463Y	Resistant													Mapping ganciclovir resistance in the human herpesvirus?6 U69 protein kinase	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.10510	doi.org/10.1002/jmv.10510	Marker transfer 	PRA			04/02/2021	OJCharles		Z29	A
1632	HHV6b	Z29	U69	M318V	Resistant													Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography	https://www.sciencedirect.com/science/article/pii/S0166093409003012	doi.org/10.1016/j.jviromet.2009.06.016	Marker transfer 	qPCR			04/02/2021	OJCharles		Z29	A
1633	HHV6b	Z29	U69	A447D	Resistant													Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography	https://www.sciencedirect.com/science/article/pii/S0166093409003012	doi.org/10.1016/j.jviromet.2009.06.016	Marker transfer 	qPCR			04/02/2021	OJCharles		Z29	A
1634	HHV6b	Z29	U69	C448G	Resistant													Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography	https://www.sciencedirect.com/science/article/pii/S0166093409003012	doi.org/10.1016/j.jviromet.2009.06.016	Marker transfer 	qPCR			04/02/2021	OJCharles		Z29	A
1635	HHV6b	Z29	U69	L450S	Resistant													Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography	https://www.sciencedirect.com/science/article/pii/S0166093409003012	doi.org/10.1016/j.jviromet.2009.06.016	Marker transfer 	qPCR			04/02/2021	OJCharles		Z29	A
1636	HHV6b	Z29	U69	A462D	Resistant													Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography	https://www.sciencedirect.com/science/article/pii/S0166093409003012	doi.org/10.1016/j.jviromet.2009.06.016	Marker transfer 	qPCR			04/02/2021	OJCharles		Z29	A
1637	HHV6b	Z29	U69	C463Y	Resistant													Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography	https://www.sciencedirect.com/science/article/pii/S0166093409003012	doi.org/10.1016/j.jviromet.2009.06.016	Marker transfer 	qPCR			04/02/2021	OJCharles		Z29	A
1638	HHV6b	Z29	U69	L202I	Polymorphism													Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography	https://www.sciencedirect.com/science/article/pii/S0166093409003012	doi.org/10.1016/j.jviromet.2009.06.016	Marker transfer 	qPCR			04/02/2021	OJCharles		Z29	A
1639	HHV6b	Z29	U69	L213I	Polymorphism													Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography	https://www.sciencedirect.com/science/article/pii/S0166093409003012	doi.org/10.1016/j.jviromet.2009.06.016	Marker transfer 	qPCR			04/02/2021	OJCharles		Z29	A
1640	HHV6b	HST	U38	R798I	4		213	1.2										Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection	https://www.sciencedirect.com/science/article/pii/S0166354207005001?via%3Dihub	doi.org/10.1016/j.antiviral.2007.12.004	Lab induced strain 	qPCR			04/02/2021	OJCharles		HST	A
1641	HHV6b	HST	U38	H507Y	0.84		1.1	24										Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet	https://pubmed.ncbi.nlm.nih.gov/17926642/		Lab induced strain 	qPCR			04/02/2021	OJCharles		HST	A
1642	HHV6b	HST	U38	A961V				0.7										Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet	https://pubmed.ncbi.nlm.nih.gov/17926642/		Lab induced strain 	Polymerase kinetic assay			04/02/2021	OJCharles		HST	A
1643	HHV6b	HST	U38	F292S				6										Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet	https://pubmed.ncbi.nlm.nih.gov/17926642/		Lab induced strain 	Polymerase kinetic assay			04/02/2021	OJCharles		HST	A
1644	HHV6b	HST	U38	H507Y				2.6										Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet	https://pubmed.ncbi.nlm.nih.gov/17926642/		Lab induced strain 	Polymerase kinetic assay			04/02/2021	OJCharles		HST	A
1645	HHV6b	HST	U38	T435R				1.8										Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet	https://pubmed.ncbi.nlm.nih.gov/17926642/		Lab induced strain 	Polymerase kinetic assay			04/02/2021	OJCharles		HST	A
1646	HHV6b	HST	U38	C525S				3.4										Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet	https://pubmed.ncbi.nlm.nih.gov/17926642/		Lab induced strain 	Polymerase kinetic assay			04/02/2021	OJCharles		HST	A
1647	VZV	Clinical isolate	ORF36	Q90*		Resistant												Development of Resistance to Acyclovir during Chronic Infection with the Oka Vaccine Strain of Varicella-Zoster Virus, in an Immunosuppressed Child	https://academic.oup.com/jid/article/188/7/954/820206	doi.org/10.1086/378502	Isolated strain 	TK functional kinetic assay			28/05/2021	OJCharles	Resistant Phenotype not established this was effect on TK activity (which is hand in hand) but not directly a resistance measurement	Oka	A
1648	VZV	Clinical isolate	ORF36	L92P		Resistant												Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction	https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-72-3-623#tab2	doi.org/10.1099/0022-1317-72-3-623		TK functional kinetic assay			28/05/2021	OJCharles		9883	A
1649	VZV	Clinical isolate	ORF36	L92P		Resistant												Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction	https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-72-3-623#tab2	doi.org/10.1099/0022-1317-72-3-623		TK functional kinetic assay			28/05/2021	OJCharles		9883	A
1651	VZV	Oka	ORF36	A29T		1												Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals	https://www.sciencedirect.com/science/article/pii/S0166093416300787	doi.org/10.1016/j.jviromet.2016.03.006	Isolated strain 	PRA			18/11/2021	OJCharles		Oka	A
1652	VZV	Clinical isolate	ORF36	S288L		Polymorphism												Resistance testing of clinical varicella-zoster virus strains	https://www.sciencedirect.com/science/article/pii/S0166354211002841?via%3Dihub	doi.org/10.1016/j.antiviral.2011.04.005	Isolated strain 	PRA			18/11/2021	OJCharles		Oka	A
1653	VZV	Clinical isolate	ORF36	K186R		1		1			1	1						Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades	https://www.sciencedirect.com/science/article/pii/S1386653217302433?via%3Dihub#tbl0005	doi.org/10.1016/j.jcv.2017.08.011	Isolated strain 	PRA			18/11/2021	OJCharles	Co-occurs with D545Y , needs to be tested indep	Oka	O
1654	VZV	Clinical isolate	ORF36	A319V		Polymorphism												Molecular Analysis of the Pyrimidine Deoxyribonucleoside Kinase Gene of Wild-type and Acyclovir-resistant Strains of Varicella-Zoster Virus	https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-69-10-2585#tab2	doi.org/10.1099/0022-1317-69-10-2585	Isolated strain 	PRA			18/11/2021	OJCharles		Oka	A
1655	HCMV	AD169	UL97	C592G	3.1													Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1656	HCMV	AD169	UL97	F342Y	5.9									4.2				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1657	HCMV	AD169	UL97	Y335H	0.9									1				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1658	HCMV	AD169	UL97	V345I	1.3									0.4				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1659	HCMV	AD169	UL97	L348V	0.9									1.6				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1660	HCMV	AD169	UL97	K359N	2.1									0.7				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1661	HCMV	AD169	UL97	E362D	3.8									0.1				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1662	HCMV	AD169	UL97	A378T	1									1.1				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1663	HCMV	AD169	UL97	V388M	1.2									1.1				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1664	HCMV	AD169	UL97	H415Y	1.1									0.6				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1665	HCMV	AD169	UL97	A435V	1									0.6				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1666	HCMV	AD169	UL97	C437Y	0.9									0.9				Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing	https://www.sciencedirect.com/science/article/pii/S0166354221001297?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105139	Lab induced strain 	SEAP			21/12/2021	OJCharles		AD169	A
1667	HCMV	AD169	UL54	D301N		0.2	14											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1668	HCMV	AD169	UL54	N408D		0.2	3.3											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1669	HCMV	AD169	UL54	N408K		0.1	32											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1670	HCMV	AD169	UL54	N410K		0.7	2.5											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1671	HCMV	AD169	UL54	F412C		0.2	17											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1672	HCMV	AD169	UL54	F412L		0.2	12											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1673	HCMV	AD169	UL54	K513R		3.6	14											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1674	HCMV	AD169	UL54	D515Y		0.6	2.2											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1675	HCMV	AD169	UL54	L516P		0.2	5.3											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1676	HCMV	AD169	UL54	P522S		0.2	4.4											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1677	HCMV	AD169	UL54	L545W		0.3	6.4											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1678	HCMV	AD169	UL54	Q578H		8.6	2.9	Resistant										Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1679	HCMV	AD169	UL54	T700A		4.6	1.7	Resistant										Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1680	HCMV	AD169	UL54	A809V		5.2	2	Resistant										Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1681	HCMV	AD169	UL54	D981del2		0.8	3.3	Resistant										Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1682	HCMV	AD169	UL54	A987G		0.4	7.7											Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1683	HCMV	AD169	UL54	A987V		1.6	0.9	Resistant										Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility	https://www.sciencedirect.com/science/article/pii/S0166354221001716?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105181	Recombinant BAC 	SEAP			21/12/2021	OJCharles		AD169	A
1684	HSV1	HSV1-17	UL30	L49I		1	1.6	0.6										Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes	https://www.sciencedirect.com/science/article/pii/S016635422100156X?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105166	Recombinant BAC 	GFP fluorescence reduction assay			22/12/2021	OJCharles	Could incorporate metabolic data too but reps are worse	HSV1-17	A
1685	HSV1	HSV1-17	UL30	E70K		1.9		0.7										Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes	https://www.sciencedirect.com/science/article/pii/S016635422100156X?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105166	Recombinant BAC 	GFP fluorescence reduction assay			22/12/2021	OJCharles		HSV1-17	A
1686	HSV1	HSV1-17	UL30	L359I		1.4	1	0.8										Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes	https://www.sciencedirect.com/science/article/pii/S016635422100156X?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105166	Recombinant BAC 	GFP fluorescence reduction assay			22/12/2021	OJCharles		HSV1-17	A
1687	HSV1	HSV1-17	UL30	E421V		1.4	1	0.7										Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes	https://www.sciencedirect.com/science/article/pii/S016635422100156X?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105166	Recombinant BAC 	GFP fluorescence reduction assay			22/12/2021	OJCharles		HSV1-17	A
1688	HSV1	HSV1-17	UL30	P829S		1.5	1.2	0.7										Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes	https://www.sciencedirect.com/science/article/pii/S016635422100156X?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105166	Recombinant BAC 	GFP fluorescence reduction assay			22/12/2021	OJCharles		HSV1-17	A
1689	HSV1	HSV1-17	UL30	T1121M		0.8	1.6	1.1										Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes	https://www.sciencedirect.com/science/article/pii/S016635422100156X?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105166	Recombinant BAC 	GFP fluorescence reduction assay			22/12/2021	OJCharles		HSV1-17	A
1690	HSV1	HSV1-17	UL30	M1226I		1.5		1.5										Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes	https://www.sciencedirect.com/science/article/pii/S016635422100156X?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105166	Recombinant BAC 	GFP fluorescence reduction assay			22/12/2021	OJCharles		HSV1-17	A
1691	HSV1	HSV1-17	UL23	G61A		26	1.1	1										Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes	https://www.sciencedirect.com/science/article/pii/S016635422100156X?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105166	Recombinant BAC 	GFP fluorescence reduction assay			22/12/2021	OJCharles		HSV1-17	A
1692	HSV1	HSV1-17	UL30	S724N		22	4.1	11.2										Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes	https://www.sciencedirect.com/science/article/pii/S016635422100156X?via%3Dihub	doi.org/10.1016/j.antiviral.2021.105166	Recombinant BAC 	GFP fluorescence reduction assay			22/12/2021	OJCharles		HSV1-17	A
1693	HSV1	HSV1-17	UL30	Q618I		1.5		0.2										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		HSV1-17	A
1694	HSV1	HSV1-17	UL30	I619K		2.1		2.5										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		HSV1-17	A
1695	HSV1	HSV1-17	UL30	T623A		1.4		1										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		HSV1-17	A
1696	HSV1	HSV1-17	UL30	L625I		2.4		1.6										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		HSV1-17	A
1697	HSV1	HSV1-17	UL30	V694Q		1.3		1.7										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		HSV1-17	A
1698	HSV1	HSV1-17	UL30	Q697P		1.5		1.3										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		HSV1-17	A
1699	HSV1	HSV1-17	UL30	P712Y		3.7		0.6										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		HSV1-17	A
1700	HSV1	HSV1-17	UL30	A719T		3.5		2										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		HSV1-17	A
1701	HCMV	AD169	UL54	I580K	2.1			1.1										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	GLuc reporter assay			22/12/2021	OJCharles		AD169	A
1702	HCMV	AD169	UL54	T584A	1			1										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	GLuc reporter assay			22/12/2021	OJCharles		AD169	A
1703	HCMV	AD169	UL54	L586I	0.6			1										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	GLuc reporter assay			22/12/2021	OJCharles		AD169	A
1704	HCMV	AD169	UL54	V694Q	0.5			1.6										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	GLuc reporter assay			22/12/2021	OJCharles		AD169	A
1705	HCMV	AD169	UL54	Q697P	0.7			3.8										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	GLuc reporter assay			22/12/2021	OJCharles		AD169	A
1706	HCMV	AD169	UL54	A719T	2.4			2.5										Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet	https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00390-21	Recombinant BAC 	GLuc reporter assay			22/12/2021	OJCharles		AD169	A
1707	HSV1	VR-3	UL5	K356N		1		1								261		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1708	HSV1	VR-3	UL5	G352C		1		1								25		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1709	HSV1	VR-3	UL5	G352V		1		1								3		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1710	HSV1	VR-3	UL5	M355T		1		1								6		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1711	HSV1	VR-3	UL5	E34K		1		1								1.5		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1712	HSV1	VR-3	UL5	I341S		1		1								1.5		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1713	HSV1	VR-3	UL5	C477D		1		1								1.5		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1714	HSV1	VR-3	UL52	F360V		1		1								158		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1715	HSV1	VR-3	UL52	F360C		1		1								25		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1716	HSV1	VR-3	UL52	N902T		1		1								6		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1717	HSV1	VR-3	UL52	Y222C		1		1								1.5		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1718	HSV1	VR-3	UL52	F294L		1		1								1.5		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1719	HSV1	VR-3	UL52	S364G		1		1								1		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Recombinant BAC 	PRA			22/12/2021	OJCharles		VR-3	A
1720	HSV2	UW-268	UL5	K355N												2800		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Lab induced strain 	PRA			22/12/2021	OJCharles		VR-3	A
1721	HSV2	UW-268	UL5	G351R												2196		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Lab induced strain 	PRA			22/12/2021	OJCharles		UW-268	A
1722	HSV2	UW-268	UL5	K355E												8		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Lab induced strain 	PRA			22/12/2021	OJCharles		UW-268	A
1723	HSV2	UW-268	UL5	I340V												2.1		Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus	https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed	doi.org/10.1128/AAC.00494-21	Lab induced strain 	PRA			22/12/2021	OJCharles		UW-268	A
1724	HCMV	Toledo	UL54	T700A	0.9		0.7	7.6										Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance	https://www.frontiersin.org/articles/10.3389/fmicb.2022.771978/full	doi.org/10.3389/fmicb.2022.771978	Recombinant BAC 	PRA			04/03/2022	OJCharles		Toledo	A
1725	HCMV	Toledo	UL54	H600L	11.1		4.9	5.2										Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance	https://www.frontiersin.org/articles/10.3389/fmicb.2022.771978/full	doi.org/10.3389/fmicb.2022.771978	Recombinant BAC 	PRA			04/03/2022	OJCharles		Toledo	A
1726	HCMV	Toledo	UL54	E756G	1		1.8	8.8										Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance	https://www.frontiersin.org/articles/10.3389/fmicb.2022.771978/full	doi.org/10.3389/fmicb.2022.771978	Recombinant BAC 	PRA			04/03/2022	OJCharles		Toledo	A
1727	HCMV	Toledo	UL54	H600L	1.4		0.7	37										Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance	https://www.frontiersin.org/articles/10.3389/fmicb.2022.771978/full	doi.org/10.3389/fmicb.2022.771978	Recombinant BAC 	PRA	UL54	T700A	04/03/2022	OJCharles		Toledo	A
1729	Adeno	ad5	pol	V303I			1.9		2.1									Cidofovir Diphosphate Inhibits Adenovirus 5 DNA Polymerase via both Nonobligate Chain Termination and Direct Inhibition, and Polymerase Mutations Confer Cidofovir Resistance on Intact Virus	https://aac.asm.org/content/aac/63/1/e01925-18.full.pdf	doi.org/10.1128/AAC.01925-18	Lab induced strain 	Polymerase kinetic assay	pol	T87I	04/02/2022	OJCharles	co-occuring uncharacterised mutations		O
1730	HCMV	AD169	UL97	C480F	17.5			0.84						10				Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/224/6/1024/6105173	doi.org/10.1093/infdis/jiab029	Recombinant BAC 	GFP fluorescence reduction assay			05/08/2023	OJCharles		AD169	A
1731	HSV1	F	UL23	T63A	10													Drug resistance of herpes simplex virus type 1Structural considerations at the molecular level of the thymidine kinase	https://febs.onlinelibrary.wiley.com/doi/abs/10.1046/j.1432-1327.1998.2550472.x?sid=nlm%3Apubmed	doi.org/10.1046/j.1432-1327.1998.2550472.x	Marker transfer 	TK functional kinetic assay			17/05/2022	OJCharles	fold change guessed, no tk activity	F	A
1732	HSV1	F	UL23	T63S	5													Drug resistance of herpes simplex virus type 1Structural considerations at the molecular level of the thymidine kinase	https://febs.onlinelibrary.wiley.com/doi/abs/10.1046/j.1432-1327.1998.2550472.x?sid=nlm%3Apubmed	doi.org/10.1046/j.1432-1327.1998.2550472.x	Marker transfer 	TK functional kinetic assay			17/05/2022	OJCharles		F	A
1733	HCMV	AD169	UL56	R246C	0.6		1.8	0.9		0.8				0.5				Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045154/	doi.org/10.1128/spectrum.00191-22	Recombinant BAC 	GFP fluorescence reduction assay			09/10/2022	OJCharles		AD169	A
1734	HCMV	AD169	UL51	D12E						1.4								First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure	https://www.sciencedirect.com/science/article/pii/S0166354222001309	doi.org/10.1016/j.antiviral.2022.105361	Recombinant BAC 	GFP fluorescence reduction assay			09/10/2022	OJCharles		AD169	A
1735	HCMV	AD169	UL51	A95V						13.8								First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure	https://www.sciencedirect.com/science/article/pii/S0166354222001309	doi.org/10.1016/j.antiviral.2022.105361	Recombinant BAC 	GFP fluorescence reduction assay			09/10/2022	OJCharles		AD169	A
1736	HCMV	AD169	UL51	V113L						1.5								First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure	https://www.sciencedirect.com/science/article/pii/S0166354222001309	doi.org/10.1016/j.antiviral.2022.105361	Recombinant BAC 	GFP fluorescence reduction assay			09/10/2022	OJCharles		AD169	A
1737	HCMV	AD169	UL51	A95V						128								First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure	https://www.sciencedirect.com/science/article/pii/S0166354222001309	doi.org/10.1016/j.antiviral.2022.105361	Recombinant BAC 	GFP fluorescence reduction assay	UL56	L257I	09/10/2022	OJCharles		AD169	A
1738	HCMV	AD169	UL56	V231L						8.8								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917?via%3Dihub#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1739	HCMV	AD169	UL56	Q234R						2								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917?via%3Dihub#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1740	HCMV	AD169	UL56	L243P						1								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917?via%3Dihub#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1741	HCMV	AD169	UL56	S262C						1								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917?via%3Dihub#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1742	HCMV	AD169	UL56	L328I						1.4								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917?via%3Dihub#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1743	HCMV	AD169	UL56	H335Y						0.8								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917?via%3Dihub#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1744	HCMV	AD169	UL56	E339G						1.2								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917?via%3Dihub#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1745	HCMV	AD169	UL56	K350R						1								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917?via%3Dihub#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1746	HCMV	AD169	UL56	V363I						3.7								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917?via%3Dihub#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1747	HCMV	AD169	UL56	N368I						1.3								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917?via%3Dihub#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1748	HCMV	AD169	UL56	R369K						4.9								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917?via%3Dihub#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1749	HCMV	AD169	UL56	T399I						0.8								Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing	https://www.sciencedirect.com/science/article/pii/S0166354222001917?via%3Dihub#bib4	doi.org/10.1016/j.antiviral.2022.105422	Recombinant BAC 	SEAP			09/10/2022	OJCharles		AD169	A
1750	HCMV	AD169	UL54	G441S	Polymorphism		Polymorphism	Polymorphism										Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA			05/08/2023	OJCharles		AD169	A
1751	HCMV	AD169	UL54	A543V			Resistant											Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA	UL54	M460I	05/08/2023	OJCharles	co-occurs with M460I which causes GCVr and has not been tested against CDV but given GCVr it is more likely it causes CDVr and A543V is therefore hard to determine	AD169	O
1752	HCMV	AD169	UL54	F460S	Polymorphism		Polymorphism	Polymorphism										Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA			05/08/2023	OJCharles		AD169	A
1753	HCMV	AD169	UL54	R512C	Polymorphism		Polymorphism	Polymorphism										Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA			05/08/2023	OJCharles		AD169	A
1754	HCMV	AD169	UL54	A928T	Resistant		Resistant	Resistant										Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA			05/08/2023	OJCharles	no other mutations noted	AD169	A
1755	HCMV	AD169	UL56	F345L	1.42		1.67	1		1								Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA			05/08/2023	OJCharles		AD169	A
1756	HCMV	AD169	UL56	P800L	0.23		0.13	1		1.1								Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection	https://academic.oup.com/jid/article-abstract/226/9/1528/6672993	doi.org/10.1093/infdis/jiac349	Isolated strain 	PRA			05/08/2023	OJCharles		AD169	A
1757	HSV1	KOS	UL30	Q727R		Resistant		Resistant										A Herpes Simplex Virus 1 DNA Polymerase Multidrug Resistance Mutation Identified in a Patient With Immunodeficiency and Confirmed by Gene Editing	https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiad184/7177683?redirectedFrom=fulltext	doi.org/10.1093/infdis/jiad184	Marker transfer 	Cytopathic effect			05/08/2023	OJCharles		KOS	A
1758	HSV1	Clinical isolate	UL30	R264C	1.9	0.6	1.2	0.7			1.2	2						A Herpes Simplex Virus 1 DNA Polymerase Multidrug Resistance Mutation Identified in a Patient With Immunodeficiency and Confirmed by Gene Editing	https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiad184/7177683?redirectedFrom=fulltext	doi.org/10.1093/infdis/jiad184	Isolated strain 	Cytopathic effect			05/08/2023	OJCharles	lost ref	KOS	P
1759	HSV1	Clinical isolate	UL30	T245M	199	297	1.2	0.9			545	467						A Herpes Simplex Virus 1 DNA Polymerase Multidrug Resistance Mutation Identified in a Patient With Immunodeficiency and Confirmed by Gene Editing	https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiad184/7177683?redirectedFrom=fulltext	doi.org/10.1093/infdis/jiad184	Isolated strain 	Cytopathic effect			05/08/2023	OJCharles	lost ref	KOS	O
1760	HCMV	AD169	UL56	V231L						5.6								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1761	HCMV	AD169	UL56	L241P						173								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1762	HCMV	AD169	UL56	R369M						16								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1763	HCMV	AD169	UL89	D344E						1.6								A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance	https://www.sciencedirect.com/science/article/pii/S0166354217306393	doi.org/10.1016/j.antiviral.2017.10.019	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1764	HCMV	AD169	UL56	V231L						8.1								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1765	HCMV	AD169	UL56	V236M						49								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1766	HCMV	AD169	UL56	L257F						14								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1767	HCMV	AD169	UL56	C325Y						8800								New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir	https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf	doi.org/10.1128/AAC.00922-18	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1768	HCMV	AD169	UL27	R448P										1.5				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1769	HCMV	AD169	UL27	D534Y										1.4				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1770	HCMV	AD169	UL97	I324V										0.6				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1771	HCMV	AD169	UL97	S334G										1.1				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1772	HCMV	AD169	UL27	R233S										2				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP	UL97	S334G	07/08/2023	OJCharles		AD169	A
1773	HCMV	AD169	UL97	L337M										7.2				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP	UL27	R233S	07/08/2023	OJCharles		AD169	A
1774	HCMV	AD169	UL97	V353A										12				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1775	HCMV	AD169	UL97	S386L										0.9				Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo	https://www.sciencedirect.com/science/article/pii/S0166354212001283	doi.org/10.1016/j.antiviral.2012.05.013	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1776	HCMV	Clinical isolate	UL97	M460V	6									1				Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action	https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002	doi.org/10.1128/aac.46.8.2365-2372.2002	Isolated strain 	PCR DNA hybridization assay			07/08/2023	OJCharles		AD169	A
1777	HCMV	Clinical isolate	UL97	H520E	5.2									1.6				Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action	https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002	doi.org/10.1128/aac.46.8.2365-2372.2002	Isolated strain 	PCR DNA hybridization assay			07/08/2023	OJCharles		AD169	A
1778	HCMV	Clinical isolate	UL97	A594V	6													Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action	https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002	doi.org/10.1128/aac.46.8.2365-2372.2002	Isolated strain 	PCR DNA hybridization assay			07/08/2023	OJCharles		AD169	A
1779	HCMV	Clinical isolate	UL54	T700A	2.2									0.8				Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action	https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002	doi.org/10.1128/aac.46.8.2365-2372.2002	Isolated strain 	PCR DNA hybridization assay			07/08/2023	OJCharles		AD169	A
1780	HCMV	Clinical isolate	UL97	L397R	1									34				Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action	https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002	doi.org/10.1128/aac.46.8.2365-2372.2002	Isolated strain 	PCR DNA hybridization assay			07/08/2023	OJCharles		AD169	A
1781	HCMV	AD169	UL27	V353A										16				Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir	https://aac.asm.org/content/53/1/81	doi.org/10.1128/AAC.01177-08	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1782	HCMV	AD169	UL97	V353A	1.7									15				Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant	https://jvi.asm.org/content/82/1/246.short	doi.org/10.1128/JVI.01787-07	Marker transfer	SEAP			07/08/2023	OJCharles		AD169	A
1783	HCMV	AD169	UL97	H587Y	1									1				Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant	https://jvi.asm.org/content/82/1/246.short	doi.org/10.1128/JVI.01787-07	Marker transfer	SEAP			07/08/2023	OJCharles		AD169	A
1784	HCMV	AD169	UL27	R233S										4.7				Mutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to Maribavir	https://journals.asm.org/doi/full/10.1128/jvi.78.13.7124-7130.2004	doi.org/10.1128/jvi.78.13.7124-7130.2004	Marker Transfer	PRA			07/08/2023	OJCharles		AD169	A
1785	HCMV	AD169	UL27	W362R										2				Mutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to Maribavir	https://journals.asm.org/doi/full/10.1128/jvi.78.13.7124-7130.2004	doi.org/10.1128/jvi.78.13.7124-7130.2004	Marker Transfer	PRA			07/08/2023	OJCharles		AD169	A
1786	HCMV	AD169	UL97	M460V	7									0.3				Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance	https://academic.oup.com/jid/article-lookup/doi/10.1086/518514	doi.org/10.1086/518514	Marker Transfer 	SEAP			07/08/2023	OJCharles		AD169	A
1787	HCMV	AD169	UL97	V353A										10				Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance	https://aac.asm.org/content/aac/57/7/3375.full.pdf		Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1788	HCMV	AD169	UL97	M460I											11			Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance	https://aac.asm.org/content/aac/57/7/3375.full.pdf		Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1789	HCMV	AD169	UL97	C592G	2.7													Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance	https://aac.asm.org/content/aac/57/7/3375.full.pdf		Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1790	HCMV	AD169	UL97	A594V	8.3													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1791	HCMV	AD169	UL97	C603R	8.3													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1792	HCMV	AD169	UL97	V665I	1.1													Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/	doi.org/10.1128/AAC.00186-10	Recombinant BAC 	SEAP			07/08/2023	OJCharles		AD169	A
1793	HCMV	AD169	UL97	K355M	25										13			Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions	https://journals.asm.org/doi/full/10.1128/aac.01726-13	doi.org/10.1128/aac.01726-13	Recombinant BAC 	PRA			07/08/2023	OJCharles		AD169	A
1794	HCMV	Towne	UL97	C592G	2.5													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			07/08/2023	OJCharles		Towne	A
1795	HCMV	Towne	UL97	L634Q	1.1													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			07/08/2023	OJCharles		Towne	A
1796	HCMV	Towne	UL97	C607F	1.6													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			07/08/2023	OJCharles		Towne	A
1797	HCMV	AD169	UL97	L595S	4.9													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			07/08/2023	OJCharles		AD169	A
1798	HCMV	AD169	UL97	C592G	2.6													Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir	https://academic.oup.com/jid/article/185/2/162/2191141	doi.org/10.1086/338362	Marker Transfer 	PRA			07/08/2023	OJCharles		AD169	A
1799	HCMV	Clinical Isolate	UL97	L595F	1		0.4	1.5										High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes	https://academic.oup.com/jid/article/176/1/69/901024	doi.org/10.1086/514041	Isolated strain 	PRA			07/08/2023	OJCharles			A
1800	HCMV	Clinical Isolate	UL97	A594V	1.7		1.7	1.1										High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes	https://academic.oup.com/jid/article/176/1/69/901024	doi.org/10.1086/514041	Isolated strain 	PRA			07/08/2023	OJCharles			A
1801	HCMV	Clinical Isolate	UL97	M460V	1.7		1.2	0.9										High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes	https://academic.oup.com/jid/article/176/1/69/901024	doi.org/10.1086/514041	Isolated strain 	PRA			07/08/2023	OJCharles			A
1802	HCMV	Clinical Isolate	UL97	M460I	2.2		1	0.6										High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes	https://academic.oup.com/jid/article/176/1/69/901024	doi.org/10.1086/514041	Isolated strain 	PRA			07/08/2023	OJCharles			A
1803	HCMV	Clinical Isolate	UL97	L595S	4		1	1										Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles			A
1804	HCMV	Clinical Isolate	UL97	H520Q	3.2		0.5	1.5										Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles			A
1805	HCMV	Clinical Isolate	UL97	A594P	2.6		2.5	0.7										Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles			A
1806	HCMV	Clinical Isolate	UL54	F412S	2.3		16	1										Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles			A
1807	HCMV	Clinical Isolate	UL97	A594V	1.8													Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles	large discrepencies between reps		O
1808	HCMV	Clinical Isolate	UL97	C607Y	4													Analysis and Characterization of Antiviral Drugâ€“Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients	https://academic.oup.com/jid/article/186/6/760/2191110	doi.org/10.1086/342844	Isolated strain 	PRA			07/08/2023	OJCharles			A
1809	HCMV		UL97	L595F	7													Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma	https://www.jci.org/articles/view/117648	doi.org/10.1172/jci117648	Isolated strain 	PRA			14/08/2023	OJCharles			A
1810	HCMV		UL97	T659I	4													Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma	https://www.jci.org/articles/view/117648	doi.org/10.1172/jci117648	Isolated strain 	PRA			14/08/2023	OJCharles			A
1811	HCMV		UL54	V715M	1			5.5										Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS	https://journals.asm.org/doi/10.1128/JVI.70.3.1390-1395.1996	doi.org/10.1128/jvi.70.3.1390-1395.1996	Marker Transfer	PRA			14/08/2023	OJCharles		AD169	A
1812	HCMV	AD169	UL54	N495K 	1		2.5	5.6										Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR	https://www.sciencedirect.com/science/article/pii/S0166354208004221	doi.org/10.1016/j.antiviral.2008.09.009	Marker Transfer	PRA			14/08/2023	OJCharles		AD169	A
1813	HCMV	AD169	UL54	L545S	8		10											Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR	https://www.sciencedirect.com/science/article/pii/S0166354208004221	doi.org/10.1016/j.antiviral.2008.09.009	Marker Transfer	PRA			14/08/2023	OJCharles		AD169	A
1814	HCMV		UL97	A594V	10													Antiviral Susceptibilities and Analysis of UL97 and DNA Polymerase Sequences of Clinical Cytomegalovirus Isolates from Immunocompromised Patients	https://academic.oup.com/jid/article/175/5/1087/853432	doi.org/10.1086/516446	Isolated strain 	PRA			14/08/2023	OJCharles			A
1815	HCMV		UL97	A594T	5													Antiviral Susceptibilities and Analysis of UL97 and DNA Polymerase Sequences of Clinical Cytomegalovirus Isolates from Immunocompromised Patients	https://academic.oup.com/jid/article/175/5/1087/853432	doi.org/10.1086/516446	Isolated strain 	PRA			14/08/2023	OJCharles			A
1816	HCMV		UL97	C603W	Resistant		Polymorphism	Polymorphism										Drug-resistant cytomegalovirus in transplant recipients: a French cohort study	https://academic.oup.com/jac/article/65/12/2628/755060#13268428	doi.org/10.1093/jac/dkq368	Isolated strain 	PCR DNA hybridization assa			14/08/2023	OJCharles		AD169	A
1817	HCMV		UL54	A834P	Resistant		Resistant	Resistant										Drug-resistant cytomegalovirus in transplant recipients: a French cohort study	https://academic.oup.com/jac/article/65/12/2628/755060#13268428	doi.org/10.1093/jac/dkq368	Isolated strain 	PCR DNA hybridization assa			14/08/2023	OJCharles		AD169	A
1818	HCMV		UL97	M460V	8.2													Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients	https://www.sciencedirect.com/science/article/pii/S1386653206004161	www.sciencedirect.com/science/article/pii/S1386653206004161	Marker Transfer	SEAP			14/08/2023	OJCharles		AD169	A
1819	HCMV		UL54	D413A	6.5		10	0.8										Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients	https://www.sciencedirect.com/science/article/pii/S1386653206004161	www.sciencedirect.com/science/article/pii/S1386653206004161	Marker Transfer	SEAP			14/08/2023	OJCharles		AD169	A
1820	HCMV	Towne	UL54	D588N	3.8		2.7	3.2										How Evolution of Mutations Conferring Drug Resistance Affects Viral Dynamics and Clinical Outcomes of Cytomegalovirus-Infected Hematopoietic Cell Transplant Recipients	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC540138/	doi.org/10.1128%2FJCM.43.1.208-213.2005	Marker Transfer 	PRA			14/08/2023	OJCharles		Towne	A
1821	HCMV		UL97	C592F	4	0.8	1.8	1.6										Aciclovir Selects for Ganciclovir-Cross-Resistance ofHuman Cytomegalovirus In Vitro That is Only in PartExplained by Known Mutations in the UL97 Protein	https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.2003	doi.org/10.1002/jmv.2003	Lab derived mutant 	PRA			14/08/2023	OJCharles			A
1822	HCMV		UL97	K599M	1.5	1.6	1	3.8										Aciclovir Selects for Ganciclovir-Cross-Resistance ofHuman Cytomegalovirus In Vitro That is Only in PartExplained by Known Mutations in the UL97 Protein	https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.2003	doi.org/10.1002/jmv.2003	Lab derived mutant 	PRA			14/08/2023	OJCharles	Reported as L599M compared to AD169 which has K599 and L600. Assuming the correct mutation is K599M		A
1823	HCMV		UL54	F412C	3.6		10	2.5										Evolution of Mutations Conferring Multidrug Resistance during Prophylaxis and Therapy for Cytomegalovirus Disease	https://academic.oup.com/jid/article/176/3/786/872103	doi.org/10.1086/517302	Lab derived mutant 	PRA			14/08/2023	OJCharles		AD169	A
1824	HCMV		UL54	L802M	3.6		1.8	11										Evolution of Mutations Conferring Multidrug Resistance during Prophylaxis and Therapy for Cytomegalovirus Disease	https://academic.oup.com/jid/article/176/3/786/872103	doi.org/10.1086/517302	Lab derived mutant 	PRA			14/08/2023	OJCharles		AD169	A
1825	HCMV	AD169	UL97	D605E	0.6													GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E	https://www.sciencedirect.com/science/article/pii/S0166354201002029	doi.org/10.1016/S0166-3542(01)00202-9	Marker Transfer	PRA			14/08/2023	OJCharles		AD169	A
1826	HCMV	AD169	UL97	A594P	4.6													GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E	https://www.sciencedirect.com/science/article/pii/S0166354201002029	doi.org/10.1016/S0166-3542(01)00202-9	Marker Transfer	PRA			14/08/2023	OJCharles		AD169	A
1827	HCMV	AD169	UL97	A594P	3.8													GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E	https://www.sciencedirect.com/science/article/pii/S0166354201002029	doi.org/10.1016/S0166-3542(01)00202-9	Marker Transfer	PRA	UL97	D605E	14/08/2023	OJCharles		AD169	A
1828	HCMV	TB40	UL97	M460V	5.9													Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay	https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759	doi.org/10.1016/j.jcv.2015.06.090	Recombinant BAC	PRA			14/08/2023	OJCharles		TB40	A
1829	HCMV	TB40	UL97	I610T	2.6													Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay	https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759	doi.org/10.1016/j.jcv.2015.06.090	Recombinant BAC	PRA			14/08/2023	OJCharles		TB40	A
1830	HCMV	TB40	UL97	E596D	1.3													Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay	https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759	doi.org/10.1016/j.jcv.2015.06.090	Recombinant BAC	PRA			14/08/2023	OJCharles		TB40	A
1831	HCMV	TB40	UL54	D515E	2.4		1.6	1.1										Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay	https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759	doi.org/10.1016/j.jcv.2015.06.090	Recombinant BAC	PRA			14/08/2023	OJCharles		TB40	A
1832	HCMV	TB40	UL54	I521T	2.1		4.9	1										Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay	https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759	doi.org/10.1016/j.jcv.2015.06.090	Recombinant BAC	PRA			14/08/2023	OJCharles		TB40	A
1833	HCMV	TB40	UL54	L516M	1.3		1.1	1.2										Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation	https://www.sciencedirect.com/science/article/abs/pii/S0166354213002866	https://doi.org/10.1016/j.antiviral.2013.09.026	Recombinant BAC	PRA			14/08/2023	OJCharles		TB40	A
1834	HCMV	Clinical isolate	UL97	M460V	15.5													Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation	https://www.sciencedirect.com/science/article/abs/pii/S0166354213002866	https://doi.org/10.1016/j.antiviral.2013.09.026	Isolated strain	PRA			14/08/2023	OJCharles		TB40	A
1835	HCMV	Clinical isolate	UL97	M615V	1.1													Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis	https://www.sciencedirect.com/science/article/abs/pii/S1386653210000181	doi.org/10.1016/j.jcv.2010.01.009	Recombinant BAC 	PRA			14/08/2023	OJCharles			A
1836	HCMV		UL97	C603R	3.6													Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis	https://www.sciencedirect.com/science/article/abs/pii/S1386653210000181	doi.org/10.1016/j.jcv.2010.01.009	Recombinant BAC 	PRA			14/08/2023	OJCharles			A
1837	HCMV	AD169	UL97	C592G	3													Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene	https://journals.asm.org/doi/10.1128/JCM.00391-17	doi.org/10.1128/jcm.00391-17	Recombinant BAC 	SEAP			14/08/2023	OJCharles		AD169	A
1838	HCMV	AD169	UL97	A594V	6.5													Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene	https://journals.asm.org/doi/10.1128/JCM.00391-17	doi.org/10.1128/jcm.00391-17	Recombinant BAC 	SEAP			14/08/2023	OJCharles		AD169	A
1839	HCMV	AD169	UL97	A591V	3.8													Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene	https://journals.asm.org/doi/10.1128/JCM.00391-17	doi.org/10.1128/jcm.00391-17	Recombinant BAC 	SEAP			14/08/2023	OJCharles		AD169	A
1840	HCMV	AD169	UL97	K599E	1.2													Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene	https://journals.asm.org/doi/10.1128/JCM.00391-17	doi.org/10.1128/jcm.00391-17	Recombinant BAC 	SEAP			14/08/2023	OJCharles		AD169	A
1841	HCMV	AD169	UL97	T601M	1													Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene	https://journals.asm.org/doi/10.1128/JCM.00391-17	doi.org/10.1128/jcm.00391-17	Recombinant BAC 	SEAP			14/08/2023	OJCharles		AD169	A
1842	HCMV	AD169	UL54	L897S	1		1	0.9										Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/	doi.org/10.1128/AAC.49.7.2710-2715.2005	Lab derived mutant 	SEAP			15/08/2023	OJCharles	you can draw this as we know UL97H587Y has no impact		A
1843	HCMV	AD169	UL97	M460V	9													Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/	doi.org/10.1128/AAC.49.7.2710-2715.2005	Lab derived mutant 	SEAP			15/08/2023	OJCharles			A
1844	HCMV	AD169	UL97	C592G	3		1.4	1										Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/	doi.org/10.1128/AAC.49.7.2710-2715.2005	Lab derived mutant 	SEAP			15/08/2023	OJCharles			A
1845	HCMV	AD169	UL97	A594V	9													Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/	doi.org/10.1128/AAC.49.7.2710-2715.2005	Lab derived mutant 	SEAP			15/08/2023	OJCharles			A
1846	HCMV	AD169	UL54	N408H	2		3.3	1.1										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles			A
1847	HCMV	AD169	UL54	L501F	2.6		3.8	1.3										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1848	HCMV	AD169	UL54	T503A	3.1		3.7	1.5										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1849	HCMV	AD169	UL54	K513Q	6.6		18	1										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1850	HCMV	AD169	UL54	P522T	2.1		2	1.4										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1851	HCMV	AD169	UL54	L545F	4		11	1.2										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1852	HCMV	AD169	UL54	C590F	1.6		1.6	2.3										Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1853	HCMV	AD169	UL97	A594P	8.1													Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1854	HCMV	AD169	UL97	E596Q	2.7													Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334	doi.org/10.1093/infdis/jiad293	Recombinant BAC 	SEAP			29/11/2023	OJCharles		AD169	A
1855	HSV2	Clinical isolate	UL30	L783M			2.7	7.6										Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.2195	doi.org/10.1002/jmv.2195	Isolated strain	PRA			01/12/2023	OJCharles			A
1856	HSV2	Clinical isolate	UL30	A724T			1	3.1										Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.2195	doi.org/10.1002/jmv.2195	Isolated strain	PRA			01/12/2023	OJCharles			A
1857	HSV2	Clinical isolate	UL30	S729N			1.6	3.2										Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.2195	doi.org/10.1002/jmv.2195	Isolated strain	PRA			01/12/2023	OJCharles			A
1858	HSV2	Clinical isolate	UL30	D785N			0.3	3.9										Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.2195	doi.org/10.1002/jmv.2195	Isolated strain	PRA			01/12/2023	OJCharles			A
1859	HSV2	Clinical isolate	UL30	L850I			0.3	9.2										Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.2195	doi.org/10.1002/jmv.2195	Isolated strain	PRA			01/12/2023	OJCharles			A
1860	HSV1	PDK	UL52	A899T													43	A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target	https://academic.oup.com/jac/article/61/5/1044/847175	doi.org/10.1093/jac/dkn057	Lab derived mutant 	PRA			01/12/2023	OJCharles		PDK	A
1861	HSV1	PDK	UL52	A899T													2500	A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target	https://academic.oup.com/jac/article/61/5/1044/847175	doi.org/10.1093/jac/dkn057	Lab derived mutant 	PRA	UL5	K356T	01/12/2023	OJCharles		PDK	A
1862	HSV1	PDK	UL52	A899T													100	A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target	https://academic.oup.com/jac/article/61/5/1044/847175	doi.org/10.1093/jac/dkn057	Lab derived mutant 	PRA			01/12/2023	OJCharles		PDK	A
1863	HSV1	SC16	UL5	K356Q													100	A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target	https://academic.oup.com/jac/article/61/5/1044/847175	doi.org/10.1093/jac/dkn057	Lab derived mutant 	PRA			01/12/2023	OJCharles		SC16	A
1864	HSV1	SC16	UL5	G352R													3333	A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target	https://academic.oup.com/jac/article/61/5/1044/847175	doi.org/10.1093/jac/dkn057	Lab derived mutant 	PRA			01/12/2023	OJCharles		SC16	A
1865	HSV1	SC16	UL5	K356T													100	A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target	https://academic.oup.com/jac/article/61/5/1044/847175	doi.org/10.1093/jac/dkn057	Lab derived mutant 	PRA			01/12/2023	OJCharles		SC16	A
1866	HSV1	SC16	UL5	K356T													124	A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target	https://academic.oup.com/jac/article/61/5/1044/847175	doi.org/10.1093/jac/dkn057	Lab derived mutant 	PRA			01/12/2023	OJCharles		SC16	A
1867	HSV1	SC16	UL5	M355T													15	High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57â€“1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1	https://journals.sagepub.com/doi/10.1177/095632020701800102	doi.org/10.1177/0956320207018001	Lab derived mutant 	PRA			01/12/2023	OJCharles	my concern with this paper is that they do not cover other important genes eg BAY-Pr1 is 50fold resistance with no ul5 mutations discard all?		A
1868	HSV1	SC16	UL5	K356T													125	High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57â€“1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1	https://journals.sagepub.com/doi/10.1177/095632020701800102	doi.org/10.1177/0956320207018001	Lab derived mutant 	PRA			01/12/2023	OJCharles	my concern with this paper is that they do not cover other important genes eg BAY-Pr1 is 50fold resistance with no ul5 mutations discard all?		A
1869	HSV1	SC16	UL5	G352R													4000	High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57â€“1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1	https://journals.sagepub.com/doi/10.1177/095632020701800102	doi.org/10.1177/0956320207018001	Lab derived mutant 	PRA			01/12/2023	OJCharles	my concern with this paper is that they do not cover other important genes eg BAY-Pr1 is 50fold resistance with no ul5 mutations discard all?		A
1870	HSV1	PDK	UL5	A199T													50	High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57â€“1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1	https://journals.sagepub.com/doi/10.1177/095632020701800102	doi.org/10.1177/0956320207018001	Lab derived mutant 	PRA			01/12/2023	OJCharles	my concern with this paper is that they do not cover other important genes eg BAY-Pr1 is 50fold resistance with no ul5 mutations discard all?		A
1871	HSV1	PDK	UL5	K356T													2000	High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57â€“1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1	https://journals.sagepub.com/doi/10.1177/095632020701800102	doi.org/10.1177/0956320207018001	Lab derived mutant 	PRA			01/12/2023	OJCharles	my concern with this paper is that they do not cover other important genes eg BAY-Pr1 is 50fold resistance with no ul5 mutations discard all?		A
1872	HSV2	Clinical isolate	UL5	H334R													Polymorphism	"No Evidence of Pritelivir Resistance Among Herpes
Simplex Virus Type 2 Isolates After 4 Weeks of Daily
Therapy"	https://academic.oup.com/jid/article/214/2/258/2572113	doi.org/10.1093/infdis/jiw129	Isolated strain	PRA			01/12/2023	OJCharles		Bry	A
1873	HSV1		UL5	N342K													40	Antiviral drug resistance and helicaseâ€“primase inhibitors of herpes simplex virus	https://www.sciencedirect.com/science/article/abs/pii/S1368764610000609?via%3Dihub	doi.org/10.1016/j.drup.2010.11.002	Lab derived mutant 	PRA			01/12/2023	OJCharles			A
1874	HSV1		UL5	G352V													400	Antiviral drug resistance and helicaseâ€“primase inhibitors of herpes simplex virus	https://www.sciencedirect.com/science/article/abs/pii/S1368764610000609?via%3Dihub	doi.org/10.1016/j.drup.2010.11.002	Lab derived mutant 	PRA			01/12/2023	OJCharles			A
1875	HSV1		UL5	G352R													3000	Antiviral drug resistance and helicaseâ€“primase inhibitors of herpes simplex virus	https://www.sciencedirect.com/science/article/abs/pii/S1368764610000609?via%3Dihub	doi.org/10.1016/j.drup.2010.11.002	Lab derived mutant 	PRA			01/12/2023	OJCharles			A
1876	HSV1		UL5	M355T													5	Antiviral drug resistance and helicaseâ€“primase inhibitors of herpes simplex virus	https://www.sciencedirect.com/science/article/abs/pii/S1368764610000609?via%3Dihub	doi.org/10.1016/j.drup.2010.11.002	Lab derived mutant 	PRA			01/12/2023	OJCharles			A
1877	HSV1		UL5	K356N													5000	Antiviral drug resistance and helicaseâ€“primase inhibitors of herpes simplex virus	https://www.sciencedirect.com/science/article/abs/pii/S1368764610000609?via%3Dihub	doi.org/10.1016/j.drup.2010.11.002	Lab derived mutant 	PRA			01/12/2023	OJCharles			A
1878	HSV1		UL5	K356Q													150	Antiviral drug resistance and helicaseâ€“primase inhibitors of herpes simplex virus	https://www.sciencedirect.com/science/article/abs/pii/S1368764610000609?via%3Dihub	doi.org/10.1016/j.drup.2010.11.002	Lab derived mutant 	PRA			01/12/2023	OJCharles			A
1879	HSV2		UL23	A190V		8												Genotypic testing improves detection of antiviral resistance in human herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S1386653223001774	doi.org/10.1016/j.jcv.2023.105554	Isolated strain	PRA			01/12/2023	OJCharles			A
1880	HSV2		UL30	T1200A		1												Genotypic testing improves detection of antiviral resistance in human herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S1386653223001774	doi.org/10.1016/j.jcv.2023.105554	Isolated strain	PRA			01/12/2023	OJCharles			A
1881	HSV1	KOS	UL30	Y941H		10		Resistant										A Point Mutation within a Distinct Conserved Region of the Herpes Simplex Virus DNA Polymerase Gene Confers Drug Resistance	https://journals.asm.org/doi/10.1128/jvi.66.3.1774-1776.1992	doi.org/10.1128/jvi.66.3.1774-1776.1992	Marker Transfer	PRA			01/12/2023	OJCharles		KOS	A
1882	HSV1	Clinical isolate	UL30	L216I	1	1		1										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles		TAS	A
1883	HSV1	Clinical isolate	UL30	I890M	1	3.5		5.7										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles		TAS	A
1884	HSV1	Clinical isolate	UL23	L327R	4.2	10		0.6										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles		TAS	A
1885	HSV1	Clinical isolate	UL30	R700G	0.1	0.8		1.2										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles	many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims	TAS	A
1886	HSV1	Clinical isolate	UL30	A748V	0.1	0.8		1.2										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles	many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims	TAS	A
1887	HSV1	Clinical isolate	UL30	K908Q	0.1	0.8		1.2										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles	many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims	TAS	A
1888	HSV1	Clinical isolate	UL30	A605V	0.1	3.1		3.5										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles		TAS	A
1889	HSV1	Clinical isolate	UL23	G279D		0.8												Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles		TAS	A
1890	HSV1	Clinical isolate	UL23	G56D	10	4.7		1.7										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles		TAS	A
1891	HSV1	Clinical isolate	UL30	V278A	0.1	0.3		0.3										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles	many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims	TAS	A
1892	HSV1	Clinical isolate	UL30	A1131T	0.1	0.3		0.3										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles	many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims	TAS	A
1893	HSV1	Clinical isolate	UL23	G200D	49	47		0.7										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles		TAS	A
1894	HSV1	Clinical isolate	UL30	D672N	0.3	0.5		1.3										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles	many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims	TAS	A
1895	HSV1	Clinical isolate	UL23	L32P	0.3	0.5		1.3										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles	this mutations makes no sense perhaps P31L but unsure ALSO many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims	TAS	O
1896	HSV1	Clinical isolate	UL23	R89Q	Polymorphism	Polymorphism		Polymorphism										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles	many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims	TAS	A
1897	HSV1	Clinical isolate	UL30	S724N	0.3	3.9		5										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles		TAS	A
1898	HSV1	Clinical isolate	UL30	"	A719V"	0.5	2.8		1.3										Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients	https://academic.oup.com/jid/article/215/6/865/2973094	doi.org/10.1093/infdis/jix042	Isolated strain	PRA			01/12/2023	OJCharles		TAS	A
1899	HSV1	Clinical isolate	UL23	N23S		Polymorphism												Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains	https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7	doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7	Isolated strain	PRA			01/12/2023	OJCharles		Strain 17	A
1900	HSV1	Clinical isolate	UL23	K36E		Polymorphism												Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains	https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7	doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7	Isolated strain	PRA			01/12/2023	OJCharles		Strain 17	A
1901	HSV1	Clinical isolate	UL23	L42P		Polymorphism												Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains	https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7	doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7	Isolated strain	PRA			01/12/2023	OJCharles		Strain 17	A
1902	HSV1	Clinical isolate	UL23	R89Q		Polymorphism												Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains	https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7	doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7	Isolated strain	PRA			01/12/2023	OJCharles		Strain 17	A
1903	HSV1	Clinical isolate	UL23	G240E		Polymorphism												Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains	https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7	doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7	Isolated strain	PRA			01/12/2023	OJCharles		Strain 17	A
1904	HSV1	Clinical isolate	UL23	A265T		Polymorphism												Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains	https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7	doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7	Isolated strain	PRA			01/12/2023	OJCharles		Strain 17	A
1905	HSV1	Clinical isolate	UL23	V267L		Polymorphism												Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains	https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7	doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7	Isolated strain	PRA			01/12/2023	OJCharles		Strain 17	A
1906	HSV1	Clinical isolate	UL23	P268T		Polymorphism												Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains	https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7	doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7	Isolated strain	PRA			01/12/2023	OJCharles		Strain 17	A
1907	HSV1	Clinical isolate	UL23	R281Q		Polymorphism												Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains	https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7	doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7	Isolated strain	PRA			01/12/2023	OJCharles		Strain 17	A
1908	HSV1	Clinical isolate	UL23	D286E		Polymorphism												Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains	https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7	doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7	Isolated strain	PRA			01/12/2023	OJCharles		Strain 17	A
1909	HSV1	Clinical isolate	UL23	P355Q		Polymorphism												Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains	https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7	doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7	Isolated strain	PRA			01/12/2023	OJCharles		Strain 17	A
1910	HSV1	Clinical isolate	UL23	N376P		Polymorphism												Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains	https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7	doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7	Isolated strain	PRA			01/12/2023	OJCharles		Strain 17	A
1911	HSV1	Clinical isolate	UL23	N23S		1												Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985	doi.org/10.1002/jmv.28985	Isolated strain	PRA			01/12/2023	OJCharles	reported as S23N	KOS	A
1912	HSV1	Clinical isolate	UL30	E226D		1												Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985	doi.org/10.1002/jmv.28985	Isolated strain	PRA			01/12/2023	OJCharles		KOS	A
1913	HSV1	Clinical isolate	UL30	A566T		1												Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985	doi.org/10.1002/jmv.28985	Isolated strain	PRA			01/12/2023	OJCharles	reported as T566A	KOS	A
1914	HSV1	Clinical isolate	UL30	E676D		1												Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985	doi.org/10.1002/jmv.28985	Isolated strain	PRA			01/12/2023	OJCharles		KOS	A
1915	HSV1	Clinical isolate	UL23	Y248D		4												Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985	doi.org/10.1002/jmv.28985	Isolated strain	PRA			01/12/2023	OJCharles		KOS	A
1916	HSV1	Clinical isolate	UL23	K36E		1												Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985	doi.org/10.1002/jmv.28985	Isolated strain	PRA			01/12/2023	OJCharles		KOS	A
1917	HSV1	Clinical isolate	UL30	R227H		1												Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985	doi.org/10.1002/jmv.28985	Isolated strain	PRA			01/12/2023	OJCharles		KOS	A
1918	HSV1	Clinical isolate	UL30	A351D		1												Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations	https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985	doi.org/10.1002/jmv.28985	Isolated strain	PRA			01/12/2023	OJCharles		KOS	A
1919	HSV1	M13	UL23	G56V		100												Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity	https://www.sciencedirect.com/science/article/abs/pii/004268228890308X	doi.org/10.1016/0042-6822(88)90308-X	Marker Transfer	TK functional kinetic assay			01/12/2023	OJCharles			A
1920	HSV1	M13	UL23	G59V		100												Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity	https://www.sciencedirect.com/science/article/abs/pii/004268228890308X	doi.org/10.1016/0042-6822(88)90308-X	Marker Transfer	TK functional kinetic assay			01/12/2023	OJCharles			A
1921	HSV1	M13	UL23	G61V		100												Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity	https://www.sciencedirect.com/science/article/abs/pii/004268228890308X	doi.org/10.1016/0042-6822(88)90308-X	Marker Transfer	TK functional kinetic assay			01/12/2023	OJCharles			A
1922	HSV1	M13	UL23	K62I		100												Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity	https://www.sciencedirect.com/science/article/abs/pii/004268228890308X	doi.org/10.1016/0042-6822(88)90308-X	Marker Transfer	TK functional kinetic assay			01/12/2023	OJCharles			A
1923	HSV1	M13	UL23	T63S		0.8												Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity	https://www.sciencedirect.com/science/article/abs/pii/004268228890308X	doi.org/10.1016/0042-6822(88)90308-X	Marker Transfer	TK functional kinetic assay			01/12/2023	OJCharles			A
1924	HSV1	M13	UL23	T63A		100												Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity	https://www.sciencedirect.com/science/article/abs/pii/004268228890308X	doi.org/10.1016/0042-6822(88)90308-X	Marker Transfer	TK functional kinetic assay			01/12/2023	OJCharles			A
1925	HSV1	Clinical isolate	UL23	R527Q		200												Herpes Simplex Virus Isolates from an Immunocompromised Patient who Failed to Respond to Acyclovir Treatment Express Thymidine Kinase with Altered Substrate Specificity	https://journals.sagepub.com/doi/10.1177/095632029100200504	doi.org/10.1177/09563202910020050	Isolated strain	PRA			01/12/2023	OJCharles	polymerase was not sequenced	SC16	A
1926	HSV2	Clinical isolate	UL23	A27T		Polymorphism												Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20061	doi.org/10.1002/jmv.20061	Isolated strain	PRA			01/12/2023	OJCharles		333	A
1927	HSV2	Clinical isolate	UL23	S29A		Polymorphism												Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20061	doi.org/10.1002/jmv.20061	Isolated strain	PRA			01/12/2023	OJCharles		333	A
1928	HSV2	Clinical isolate	UL23	R51W		Resistant												Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20061	doi.org/10.1002/jmv.20061	Isolated strain	PRA			01/12/2023	OJCharles		333	A
1929	HSV2	Clinical isolate	UL23	N78D		Polymorphism												Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20061	doi.org/10.1002/jmv.20061	Isolated strain	PRA			01/12/2023	OJCharles		333	A
1930	HSV2	Clinical isolate	UL23	L140F		Polymorphism												Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient	https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20061	doi.org/10.1002/jmv.20061	Isolated strain	PRA			01/12/2023	OJCharles		333	A
1931	HSV1	Clinical isolate	UL23	G21V		Polymorphism												Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections	https://www.nature.com/articles/s41598-022-05188-w	doi.org/10.1038/s41598-022-05188-w	Isolated strain	PRA			01/12/2023	OJCharles			A
1932	HSV1	Clinical isolate	UL23	D162N		64												Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections	https://www.nature.com/articles/s41598-022-05188-w	doi.org/10.1038/s41598-022-05188-w	Isolated strain	PRA			01/12/2023	OJCharles			A
1933	HSV1	HM3PP	UL23	R212K		Resistant												Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections	https://www.nature.com/articles/s41598-022-05188-w	doi.org/10.1038/s41598-022-05188-w	Recombinant BAC 	PRA			01/12/2023	OJCharles		HM3PP	A
1934	HSV1	HM3PP	UL23	E225K		Resistant												Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections	https://www.nature.com/articles/s41598-022-05188-w	doi.org/10.1038/s41598-022-05188-w	Recombinant BAC 	PRA			01/12/2023	OJCharles		HM3PP	A
1935	HSV1		UL30	S724N		17		4.3										Sequential switching of DNA polymerase and thymidine kinase-mediated HSV-1 drug resistance in an immunocompromised child	https://journals.sagepub.com/doi/10.1177/135965350400900107	doi.org/10.1177/135965350400900107	Isolated strain	PRA			01/12/2023	OJCharles		KOS	A
1936	HSV1		UL23	R163H		12		1.1										Sequential switching of DNA polymerase and thymidine kinase-mediated HSV-1 drug resistance in an immunocompromised child	https://journals.sagepub.com/doi/10.1177/135965350400900107	doi.org/10.1177/135965350400900107	Isolated strain	PRA			01/12/2023	OJCharles		KOS	A
1937	HSV1	Strain17	UL30	V715G		4.6		3.4										Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases 	https://www.sciencedirect.com/science/article/abs/pii/S016635422100036X	doi.org/10.1016/j.antiviral.2021.105046	Recombinant BAC 	PRA			01/12/2023	OJCharles		Strain17	A
1938	HSV1	Strain17	UL30	V715M		3.4		1.5										Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases 	https://www.sciencedirect.com/science/article/abs/pii/S016635422100036X	doi.org/10.1016/j.antiviral.2021.105046	Recombinant BAC 	PRA			01/12/2023	OJCharles		Strain17	A
1939	HSV1	Strain17	UL30	V715S		9.2		5.6										Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases 	https://www.sciencedirect.com/science/article/abs/pii/S016635422100036X	doi.org/10.1016/j.antiviral.2021.105046	Recombinant BAC 	PRA			01/12/2023	OJCharles		Strain17	A
1940	HCMV	AD169	UL54	V715M	1.2			3.7										Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases 	https://www.sciencedirect.com/science/article/abs/pii/S016635422100036X	doi.org/10.1016/j.antiviral.2021.105046	Recombinant BAC 	PRA			01/12/2023	OJCharles		AD169	A
1941	HCMV	AD169	UL54	V715S	2.9			2.8										Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases 	https://www.sciencedirect.com/science/article/abs/pii/S016635422100036X	doi.org/10.1016/j.antiviral.2021.105046	Recombinant BAC 	PRA			01/12/2023	OJCharles		AD169	A
1942	HSV1		UL30	N522S		Polymorphism		Polymorphism										Genotypic testing improves detection of antiviral resistance in human herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S1386653223001774	doi.org/10.1016/j.jcv.2023.105554	Isolated strain	PRA			02/06/2024	OJCharles		HSV1-A	A
1943	HSV1		UL30	A566T		Polymorphism		Polymorphism										Genotypic testing improves detection of antiviral resistance in human herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S1386653223001774	doi.org/10.1016/j.jcv.2023.105554	Isolated strain	PRA			02/06/2024	OJCharles		HSV1-A	A
1944	HSV1		UL30	P1124H		Polymorphism		Polymorphism										Genotypic testing improves detection of antiviral resistance in human herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S1386653223001774	doi.org/10.1016/j.jcv.2023.105554	Isolated strain	PRA			02/06/2024	OJCharles		HSV1-A	A
1945	HSV1		UL30	A1203T		Polymorphism		Polymorphism										Genotypic testing improves detection of antiviral resistance in human herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S1386653223001774	doi.org/10.1016/j.jcv.2023.105554	Isolated strain	PRA			02/06/2024	OJCharles		HSV1-A	A
1946	HSV1		UL30	T821MÂ 		4												Genotypic testing improves detection of antiviral resistance in human herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S1386653223001774	doi.org/10.1016/j.jcv.2023.105554	Isolated strain	PRA			02/06/2024	OJCharles		HSV1-A	A
1947	HSV1		UL30	A719V		13												Genotypic testing improves detection of antiviral resistance in human herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S1386653223001774	doi.org/10.1016/j.jcv.2023.105554	Isolated strain	PRA			02/06/2024	OJCharles		HSV1-A	A
1948	HSV2		UL30	T934A		20		2.7										Genotypic testing improves detection of antiviral resistance in human herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S1386653223001774	doi.org/10.1016/j.jcv.2023.105554	Isolated strain	PRA			02/06/2024	OJCharles		HSV2-G1	A
1949	HSV2		UL30	R628C				2										Genotypic testing improves detection of antiviral resistance in human herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S1386653223001774	doi.org/10.1016/j.jcv.2023.105554	Isolated strain	PRA			02/06/2024	OJCharles		HSV2-G1	A
1950	HSV2		UL30	S729N				2.8										Genotypic testing improves detection of antiviral resistance in human herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S1386653223001774	doi.org/10.1016/j.jcv.2023.105554	Isolated strain	PRA			02/06/2024	OJCharles		HSV2-G1	A
1951	HSV1		UL23	E257K		3												Genotypic testing improves detection of antiviral resistance in human herpes simplex virus	https://www.sciencedirect.com/science/article/pii/S1386653223001774	doi.org/10.1016/j.jcv.2023.105554	Isolated strain	PRA			02/06/2024	OJCharles		HSV2-G1	A
1952	HCMV	AD169	UL56	V231L						8.1								Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation	https://www.sciencedirect.com/science/article/abs/pii/S016635422400144X	doi.org/10.1016/j.antiviral.2024.105935	Recombinant BAC 	SEAP			31/10/2024	OJCharles		AD169	A
1953	HCMV	AD169	UL56	S229Y						2								Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation	https://www.sciencedirect.com/science/article/abs/pii/S016635422400144X	doi.org/10.1016/j.antiviral.2024.105935	Recombinant BAC 	SEAP			31/10/2024	OJCharles		AD169	A
1954	HCMV	AD169	UL56	M329I						0.77								Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation	https://www.sciencedirect.com/science/article/abs/pii/S016635422400144X	doi.org/10.1016/j.antiviral.2024.105935	Recombinant BAC 	SEAP			31/10/2024	OJCharles		AD169	A
1955	HCMV	AD169	UL97	G343A	8.5									126				Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae469/7762822	doi.org/10.1093/infdis/jiae469	Recombinant BAC 	SEAP			31/10/2024	OJCharles		AD169	A
1956	HCMV	AD169	UL97	C592G	3.2													Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae469/7762822	doi.org/10.1093/infdis/jiae469	Recombinant BAC 	SEAP			31/10/2024	OJCharles		AD169	A
1957	HCMV	AD169	UL97	H411Y										17				Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae469/7762822	doi.org/10.1093/infdis/jiae469	Recombinant BAC 	SEAP			31/10/2024	OJCharles		AD169	A
1958	HCMV	AD169	UL97	G343A	7.9									272				Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection	https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae469/7762822	doi.org/10.1093/infdis/jiae469	Recombinant BAC 	SEAP	UL97	H411Y	31/10/2024	OJCharles		AD169	A
1959	HSV1	Clinical isolate	UL23	F289SÂ 														Successful treatment of acyclovirâ€resistant herpes simplex virus infection with amenamevir in a patient who received umbilical cord blood transplantation for Tâ€cell prolymphocytic leukemia	https://pmc.ncbi.nlm.nih.gov/articles/PMC11182414/#jha2899-supitem-0003	doi.org/10.1002/jha2.899					31/10/2024	OJCharles	They did perform a phenotypic assay but it lacks basic detail. Also it is not clear if the mutation or the virus was resistance the wording is too loose.		O
